WO2006035417A2 - Dihydropyrimidine microcapsule - formulations - Google Patents

Dihydropyrimidine microcapsule - formulations Download PDF

Info

Publication number
WO2006035417A2
WO2006035417A2 PCT/IE2005/000105 IE2005000105W WO2006035417A2 WO 2006035417 A2 WO2006035417 A2 WO 2006035417A2 IE 2005000105 W IE2005000105 W IE 2005000105W WO 2006035417 A2 WO2006035417 A2 WO 2006035417A2
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
minicapsules
coating
active
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IE2005/000105
Other languages
French (fr)
Other versions
WO2006035417A3 (en
Inventor
Joey Moodley
Ivan Coulter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIGMOID BIOTECHNOLOGIES Ltd
Original Assignee
SIGMOID BIOTECHNOLOGIES Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SIGMOID BIOTECHNOLOGIES Ltd filed Critical SIGMOID BIOTECHNOLOGIES Ltd
Priority to EP05786872A priority Critical patent/EP1814530A2/en
Priority to US11/663,836 priority patent/US20070292523A1/en
Priority to CA002581775A priority patent/CA2581775A1/en
Publication of WO2006035417A2 publication Critical patent/WO2006035417A2/en
Publication of WO2006035417A3 publication Critical patent/WO2006035417A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to a dosage form of a dihydropyrimidine such as nimodipine.
  • Nimodipine belongs to the class of pharmacological agents known as calcium channel blockers. The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarisation as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. Nimodipine is a yellow crystalline substance, practically insoluble in water. Nimodipine is typically formulated as soft gelatin capsule for oral administration. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition. The precise mode of action is not clear.
  • Nimodipine is a poorly water soluble drug. Drugs that are poorly water soluble must be formulated in a way that improves their solubility and hence their bioavailability. In general, a drug that is in solution or suspension when administered by the oral route is rapidly and frequently instantaneously absorbed from the gastrointestinal tract resulting in a fast therapeutic action. However in many cases it is desirable to control the rate of absorption following oral administration in order to achieve the desired plasma profile or prolongation of action of the drug.
  • nimodipine formulations may be mixed with soft foods or liquids and administered to patients via tubing directly to the stomach or small intestine.
  • a pharmaceutical formulation comprising a plurality of seamless minicapsules having a diameter of from 0.5 mm to 5 mm, the minicapsules having an encapsulating medium, and the mincapsules containing a dihydropyrimidine as an active ingredient.
  • the active ingredient is dispersed in the encapsulating medium.
  • the minicapsules comprise a core containing the active ingredient.
  • the active ingredient in the core may be solubilised in a pharmaceutically acceptable solvent and/or in a liquid phase.
  • the active ingredient may be in a solid form and/or in a semi-solid form.
  • the minicapsules may have a diameter of from 0.5 mm to 3.0 mm, from 1.2 mm to 2.0 mm, 1.4 mm to 1.8 mm.
  • At least some of the minicapsules have at least one coating to control the time and/or location of the release of the active entity.
  • At least one coating may be an immediate release coating.
  • At least one coating may be a sustained release coating.
  • the coating may comprise a sustained release and an immediate release coating.
  • At least one coating may be an enteric coating.
  • the rate-controlling coating is of a polymeric material.
  • the rate-controlling coating may comprise amino methacrylate polymeric material.
  • the rate-controlling coating may be an acrylate and/or methacrylate copolymer with quaternary ammonium.
  • the coating comprises two copolymers, one of which is highly permeable and the other of which is poorly permeable.
  • the weight ratio of highly permeable polymer to poorly permeable polymer may be from 5:95 to 15:85.
  • the ratio may be from 10:90 to 15:85.
  • the highly permeable copolymer is applied in the form of a polymer solution.
  • the highly permeable copolymer may be insoluble in water.
  • the poorly permeable copolymer is applied in the form of a polymer solution.
  • the poorly permeable copolymer may be insoluble in water.
  • the rate-controlling polymer coating contains methacrylate copolymer in the following ratio's 5:95; 10:90; 15:85 (w/w) as a mixture of
  • the copolymer mixture may comprise Eudragit RL 30D:Eudragit RS 30D.
  • the copolymer mixture may comprise Eudragit RL 12.5:Eudragit RS 12.5.
  • the coating comprises an enteric coating of a methacrylate polymer.
  • the enteric coating may comprise Eudragit S 12.5 or Eudragit SlOO providing 0 drug release in the stomach for up to 4 hours.
  • the minicapsules are coated with an immediate release coating.
  • the immediate release coating may be applied to a rate controlling coating.
  • the immediate release coating contains a pharmaceutically active ingredient.
  • An immediate release pharmaceutically active ingredient solution may be applied to a rate-controlling coating.
  • the active pharmaceutical ingredient is suspended or dissolved in the encapsulating medium of the seamless minicapsule.
  • the encapsulating medium may be of one or more of gelatine, agar, a polyethylene glycol, starch, casein, chitosan, soya bean protein, safflower protein, alginates, gellan gum, carrageenan, xanthan gum, phtalated gelatine, succinated gelatine, cellulosephtalate-acetate, oleoresin, polyvinylacetate, hydroxypropyl methyl cellulose, polymerisates of acrylic or methacrylic esters, polyvinylacetate- phtalate and combinations thereof.
  • the active ingredient is suspended or dissolved in the encapsulating medium.
  • the active ingredient may be micronised or nanonised.
  • the active ingredient may have a particle size of less than 100 microns.
  • the minicapsules comprise a core containing micronised or nanonised active ingredient and the encapsulating medium contains micronised or nanonoised active pharmaceutical ingredient suspended or dissolved in the encapsulating medium to enhance the potency of the seamless minicapsules.
  • a permeability enhancing agent may be suspended or dissolved in the encapsulating medium to enhance active bioavailability.
  • the formulation comprises a buffer layer.
  • the minicapsules are provided with or contain a bioadhesive, typically a mucoadhesive.
  • the bioadhesive comprises from 0% to 10% by weight of one or more of the following polymer classes:- polyacrylates; polyanhydrides; chitosans; carbopols; cellulose; methylcellulose; methylated deoxycellulose (m- docTM); lectins.
  • the bioadhesive may comprise from 0% to 10% by weight of one or more of the following thiolated or otherwise derivatised polymers:- polyacrylates; polyanhydrides; chitosans; carbopols; cellulose; methylcellulose; methylated deoxycellulose (m-docTM); lectins.
  • the bioadhesive comprises a coating.
  • the bioadhesive is incorporated into a part or layer of the minicapsule such as rate-controlling layer and/or the encapsulating medium.
  • the minicapsules have a layer such as an outer layer which is divided into at least two parts.
  • the parts may have the same or different compositions.
  • the formulation comprises at least two populations of sustained release minicapsules.
  • the populations may have different in-vitro dissolution profiles.
  • the invention provides a formulation of a dihydropyrimidine as the active ingerdient comprising a plurality of seamless minicapsules having at least two populations selected from:-
  • a first minicapsule population in which the minicapsules comprise a core containing the active ingredient and an encapsulating medium, the minicapsules having a diameter of from 0.5 mm to 5 mm;
  • minicapsules comprise a plurality of particles containing the active entity dispersed in an encapsulating medium, the minicapsules having a diameter of from 0.5 mm to 5 mm; and a third micro or mini particles population in which the minicapsules comprise an inert core and at least one layer around the core, the layer containing the active ingredient.
  • the dihydropyridine is nimodipine.
  • the dihydropyridine may be selected from felodipine, nicardipine nifedipine, istradipine, amlodipine and nisoldipine.
  • the minicapsules comprise a core containing nimodipine.
  • the formulation may comprise an immediate release coating which contains nimodipine.
  • the coating comprises a rate-controlling coating to achieve therapeutically effective plasma levels of the active ingredient over at least 12 hours in a human patient.
  • the coating may comprise a rate-controlling coating to achieve therapeutically effective plasma levels of the active ingredient over at least 24 hours in a human patient.
  • the formulation provides a dissolution profile in a pre-determined media such that NMT 25% of the solubilised pharmaceutical active ingredient is released after 1 hour, NMT 40% after 4 hours, NMT 70% after 8 hours and 75 to 100% after 12 hours.
  • the formulation provides a dissolution profile in pre-determined media such that 10 to 15% of the solubilised pharmaceutical active ingredient is released after 1 hour, about 15 to 30% is released after 4 hours, about 35 to 50% is released after 9 hours, about 45 to 65% is released after 12 hours and at least
  • an enteric coated minicapsule is combined with two sustained release coated minicapsules to provide a pulsed release dissolution profile.
  • the formulation is comprised of sustained release minicapsules.
  • the minicapsules provide extended residence times in the small intestine for a period of at least 5 hours, preferably at least 7 hours and more preferably in the 8-24 hours range to enable maximal bioactivity of the core active, locally or systemically.
  • the minicapsules may provide extended residence times in the nasal passage to enable maximal bioactivity of the core active agent, locally or systemically.
  • the minicapsules may provide extended residence times in the rectal passage to enable maximal bioactivity of the core active agent, locally or systemically.
  • the minicapsules may be capable of extended residence times in the vagina or intrauterine to enable maximal bioactivity of the core agent, locally or systemically.
  • minicapsules are filled into hard gelatin capsules.
  • the minicapsules may be filled into a sachet.
  • the minicapsules may be suspended in oil as a lubricant.
  • the minicapsules may be contained within a wide gauge syringe that is compatible with tube delivery.
  • the minicapsules may be in the form of a sprinkle.
  • the minicapsules may be formulated as a suppository for rectal or vaginal or intrauterine administration.
  • the minicapsules may be formulated for nasal administration.
  • the formulation contains at least one further active entity.
  • the further active entity may be a P-gp/P450 inhibitor.
  • the further active entity may be carbamazepine, valproic acid, cimetidine or a tryptan such as sumatriptan.
  • the formulation may be for treatment of Alzheimers disease wherein the further active entity comprises a cholinesterase inhibitor (such as donepezil, rivastigmine, galantamine) and one or more from the following classes: vitamins, statins, estrogen, nootrophic agents, ginkgo biloba, anti ⁇ inflammatory agents, anti-depressants, anti-psychotics, and mood stabilizers.
  • a cholinesterase inhibitor such as donepezil, rivastigmine, galantamine
  • the further active entity may be selected from one or more of a statin, a thiazidediuretic, a beta blocker, an ACE inhibitor, folic acid, co-enzyme QlO, and an anticoagulant.
  • the further active entity is present in a seamless minicapsule.
  • the further active entity may be present in at least some of the seamless minicapsules.
  • the invention also provides a formulation comprising a capsule containing a plurality of minicapsules of the invention.
  • the capsule may contain another entity.
  • the other entity may be in a powder, liquid, solid, semi-solid or gaseous form.
  • the other entity may be an active entity.
  • the formulation comprises a tablet or pellet containing a plurality of minicapsules.
  • the tablet or pellet may contain another entity.
  • the other entity may be an active entity.
  • the invention provides a controlled release technology which will allow the delivery of a dihydropyrimidine in solution to the optimum site of absorption/action in the gastrointestinal tract.
  • dihydropyrimidine formulations of the invention will allow practitioners to more easily administer active pharmaceutical formulations especially to traumatised patients within the ICU environment.
  • prior to administration of the formulations may be mixed with soft foods or liquids and administered to patients via tubing directly to the stomach or small intestine.
  • the rate-controlling polymer coat contains Methacrylate Copolymer as described in USP/NF in the following ratio's 5:95; 10:90; 15:85 as a mixture of Eudragit RL: Eudragit RS more especially Eudragit RL 12.5:Eudragit RS
  • Eudragit RL30D Eudragit RS30D or Eudragit ElOO or Eudragit E PO or a combination thereof.
  • the rate-controlling polymer coat is an Enteric Coat of Eudragit S 12.5 or Eudragit LlOO or Eudragit SlOO or Eudragit 30D or a combination thereof providing 0 drug release in the stomach for up to 4 hours.
  • an enteric coated pharmaceutical active ingredient minicapsule is combined with two SR coated pharmaceutical active ingredient minicapsules components to give Pulsed Release dissolution profile.
  • Figures 1 to 3 are graphs representing nimodipine multiparticulate seamless minicapsule dissolution profiles
  • Figures 4 to 10 are graphs which illustrate the impact of different release rates of nimodipine on % percent release - first order release
  • the invention provides a multiparticulate seamless minicapsule formulation of a dihydropyrimidine for twice or once daily administration to a patient, comprising sustained release particles each having a core containing a solubilised pharmaceutical active ingredient in a solvent or liquid phase as a seamless minicapsule, the core being coated with a rate-controlling polymer coat comprised of ammonia methacrylate copolymers in an amount sufficient to achieve therapeutically effective plasma levels of the active ingredient over at least 12 or 24 hours.
  • the pharmaceutical active seamless minicapsules were manufactured according to Freund Industrial Co 3 Ltd. US Patent No 5,882,680 (Seamless Capsule and Method of Manufacturing the Same), the entire contents of which are incorporated herein by reference.
  • the principle of seamless minicapsule formation is the utilisation of "surface tension", when two different solutions (which are not or hardly dissolved with each other) contact each other, which works by reducing the contact area of the two different solutions. After encapsulating the core solution which is ejected through an orifice with a certain diameter, with the shell solution which is also ejected through an outer orifice, the encapsulated sphere is then ejected into a cooling or hardening solution and the outer shell solution is gelled or solidified. This briefly describes the formation of seamless minicapsules.
  • the core solution is mainly a hydrophobic solution or suspension.
  • the outer shell solution is normally gelatin based.
  • a hydrophilic solution can also be encapsulated with the existence of an intermediate solution, which can avoid the direct contact of the hydrophilic core solution with the outer shell.
  • a minicapsule or a bead of shell/core mixed suspension can be processed.
  • a hydrophobic solution can be encapsulated.
  • the completed seamless minicapsules preferably have an average diameter of 0.5 - 3.00mm, more especially in the range 1.50 -1.80mm.
  • a portion or all of the sustained release particles further comprise an immediate release coating applied onto the rate-controlling polymer coat, which immediate release coating comprising a solubilised pharmaceutical active ingredient in a liquid phase.
  • the formulation can contain a portion of immediate release minicapsules each comprising a core of solubilised active pharmaceutical ingredient in a liquid phase.
  • the formulation according to the invention may also comprise at least two populations of sustained release seamless minicapsules having two different in vitro dissolution profiles.
  • the formulation according to the invention provides a dissolution profile in a pre-selected media such that about NMT 25% of the solubilised active ingredient is released after 1 hour; NMT 40% after 4 hours; NMT 70% after 8 hours; 75 to 100% after 12 hours.
  • the formulation provides a dissolution profile in a pre- determined media such that about 10 to 15% of the solubilised active ingredient is released after 1 hour; 15 to 30% is released after 4 hours; about 35 to 50% is release after 9 hours; about 45 to 65% is released after 12 hours and at least 80% is released after 24 hours.
  • greater than 80% (w/w by potency) of the formulation is comprised of sustained release seamless minicapsules.
  • the rate-controlling polymer coat contains Ammonia Methacrylate Copolymer Type A and Ammonia Methacrylate Copolymer Type B as described in USP/NF.
  • Such copolymers are manufactured and marketed by Degussa (Rohm) GmbH, Darmstadt, Germany. Most preferably the rate-controlling polymer coat contains a 5:95 or 10:90 or 15:85 mixture of Eudragit RL: Eudragit RS most especially Eudragit RL30D: Eudragit RS30D or Eudragit RL 12.5:Eudragit RS 12.5
  • sustained release seamless minicapsules following application of the rate-controlling polymer coat are dried at a temperature of about 40-50 deg C, typically for up to 24 hours.
  • the formulation is encapsulated, for example in a hard gelatin capsule.
  • the sustained release seamless minicapsules are formed by coating the active seamless minicapsule with the rate-controlling polymer coat comprised of ammonio methacrylate copolymers such as those sold under the Trade Mark EUDRAGIT.
  • EUDRAGIT polymers are polymeric lacquer substances based on acrylates and/or methacrylates.
  • the polymeric materials sold under the Trade Mark EUDRAGIT RL and EUDRAGIT RS are acrylic resins comprising copolymers of acrylic and methacrylic acid esthers with a low content of quaternary ammonium groups and are described in the "EUDRAGIT" brochure of Messrs. Degussa (Rohm Pharma) GmbH wherein detailed physical-chemical data of these products are given.
  • the ammonium groups are present as salts and give rise to the permeability of the lacquer films.
  • EUDRAGIT RL is freely permeable or RS slightly permeable, independent of pH.
  • the rate-controlling polymer coat maybe built up by applying a plurality of coats of polymer solution or suspension to the minicapsule as hereafter described.
  • the polymer solution or suspension contains the polymer(s) dissolved or suspended, respectively in a suitable aqueous or organic solvent or mixture of solvents, optionally in the presence of a lubricant.
  • Suitable lubricants are talc, stearic acid, magnesium stearate and sodium stearate.
  • a particularly preferred lubricant is talc.
  • the polymer solution or suspension may optionally include a plasticizing agent.
  • Suitable plasticizing agents include polyethylene glycol, propyleneglycol, glycerol, triacetin, dimethyl phthalate.diethyl phthalate, dibutyl phthalate, dibutyl sebacate or varying percentages of acetylated monoglycerides.
  • Suitable organic solvents include isopropyl alcohol (IPA) or acetone or a mixture.
  • the polymer solution or suspension maybe applied to the minicapsules preferably using an automated system such as a GLATT fluidised bed processor, Vector Flow
  • Polymer solution/suspension in the quantity of 5-75 ml per kilogram of minicapsules may be applied to the minicapsules using one of the listed automated fluidised bed processing systems to given target polymer coating weight.
  • the drug loaded minicapsules are coated with the rate-controlling polymers to achieve a target dissolution rate.
  • the drug released from these minicapsules is diffusion controlled as the polymer swells and becomes permeable, it allows for the controlled release in the GIT.
  • the following parameters require consideration, efficient process/conditions, drug solubility/particle size, minicapsule surface area, minicapsule diameter and coating polymer suitability.
  • the mucoadhesive controlled GIT transit minicapsules are formed by coating the active seamless minicapsules with the transit-controlling polymer coat comprised of, for example various cellulose or cellulose derivatives such as chitosan or those sold under the brand name Carbopol.
  • the minicapsule gelatine shell can be modified to comprise a sphere having two hemispheres.
  • Each hemisphere contains variable concentrations of gelatine alone or gelatine in combination with, for example, a mucoadhesive and/or an enteric material. This aspect of the invention will ensure that the active is both in close proximity with the intestinal lumen and protected from intestinal degradative attack.
  • Nimodipine is a dihydropyridine derivative and belongs to the class of pharmacological agents known as calcium channel blockers. The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarisation as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. Nimodipine is a yellow crystalline substance, practically insoluble in water. Nimodipine is typically formulated as soft gelatine capsules for oral administration.
  • Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid haemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition. The precise mode of action is not clear.
  • the invention provides an oral nimodipine multiparticulate seamless minicapsule formulation for twice or once daily administration to a patient, comprising sustained release particles each having a core containing a solubilised nimodipine in a solvent or liquid phase as a seamless minicapsule, the core being coated with a rate- controlling polymer coat comprised of ammonia methacrylate copolymers in an amount sufficient to achieve therapeutically effective plasma levels of nimodipine over at least 12 or 24 hours.
  • Nimodipine Multiparticulate Seamless Minicapsules were manufactured according to Freund Industrial Co. Ltd US Patent No. 5,882,680 (Seamless Capsule and Method of Manufacturing Same) and as described in the Summary of the Invention Section.
  • the coated minicapsules were dried in an environmentally controlled drier for between 12 to 24 hours to remove any residual solvents
  • Nimodipine seamless minicapsules uncoated (10% w/w by potency) and the polymer coated minicapsules (90% w/w by potency) from the above were blended using a suitable mechanical blender.
  • the resultant blend was filled into suitable gelatin capsules to the required target strength.
  • the core solution was treated with a High Pressure Homogeniser.
  • the median and film solutions were excluded from this example.
  • the polymer solution included a 10% plasticiser.
  • the Eudragit RS/RL were adjusted proportionately.
  • SR component 1 was as used in Example A.
  • SR component 2 was what was prepared in Example B which included the plasticiser in the polymer coating solution.
  • the Nimodipine minicapsule uncoated (10-20% w/w by potency), SR 1 (40-45% w/w by potency), SR 2 ( 40-45% w/w by potency) were blended as per Example A and filled into gelatin capsules to the target strength.
  • the core solution was pre-treated with an Ultra Centrifugal Mill.
  • Eudragit S was used as the polymer coat to provide an enteric coat with 0 drug release of up to 4 hours to the minicapsules, to target the drug release to the GIT and providing a pulsed release profile.
  • a percentage of the Enteric Coated Nimodipine minicapsules and a percentage of the coated minicapsules from Example A (as required) and a percentage of the uncoated minicapsules from Example A (as required) were blended as per in Example A and filled into suitable gelatin capsules to the target strength.
  • MCT Medium-Chain Triglycerides
  • SAIB Sucrose Acetate Isobutylate
  • the Immediate Release (IR) Nimodipine Multiparticulate Seamless Minicapsules were manufactured according to Freund Industrial Co. Ltd US Patent No. 5,882,680 (Seamless Capsule and Method of Manufacturing Same) and as described in the Summary of the Invention Section.
  • the multiparticulate minicapsules produced in this example achieved an Immediate Release Dissolution Profile as follows. Dissolution Method
  • the immediate release product was then filled into hard gelatine capsules to the required dosage strength. Furthermore the invention allows for the immediate release product to be produced in combination with a Sustained Release or Controlled Release multiparticulate minicapsule product in varying ratios of IR:SR/CR.
  • the immediate release minicapsules can be combined with a Sustained or Controlled release minicapsule component in the following ratio's (w/w by potency) e.g. 10% Immediate Release (IR) + 90% Sustained (SR)/Controlled Release (CR) minicapsules; 20% IR + 80% SR/CR; 30% IR + 70% SR/CR; 40% IR + 60% SR/CR and 50% IR + 50% SR/CR.
  • Example 2 were manufactured according to Freund Industrial Co. Ltd US Patent No.5, 882,680 (Seamless Capsule and Method of Manufacturing Same).
  • Vankel VK7025 fully auto mated with Cary Win UV Dissolution Medium: Gastric Juice with 1% SDS pH 1.2 (90OmIs)
  • the resultant multiparticulate minicapsules were filled into suitable hard gelatin capsules to the required target strength, typically 30/60/90/120 or 180 mg .Furthermore the invention allows for the combination of the SR/CR multiparticulate minicapsule with an immediate release multiparticulate minicapsule in varying ratio's of SR/CR: IR as stated in the claims (%percent Example 2+1). The IR + SR/CR combination ratio's are as per Example 1.
  • the core solution was treated with a High Pressure Homogeniser.
  • the polymer coating solution included a 10% plasticiser.
  • the Eudragit RS/RL were adjusted proportionately.
  • the process used to manufacture the multiparticulate minicapsules in this example in principle was the same as used in Example 1 & 2 with the exception that only a single orifice dosing system was used instead of the normal multiple dosing orifice system.
  • a single dosing orifice By using a single dosing orifice a uniform solid gelatine pellet or sphere is produced to a specified particle size.
  • This method produces a durable sphere in a gelatine format that includes the active ingredient which in turn allows the sphere or multipaticulate pellet to be further processes with various polymer coating systems.
  • the multiparticulate minicapsules produced in this example achieved a Sustained/Controlled Release Dissolution Profile as follows. Dissolution Method
  • the invention allows for the combination of a SR/CR multiparticulate minicapsule with another SR/CR multiparticulate minicapsule and a IR multiparticulate minicapsule or other combinations thereof in varying ratio's of SR/CR: SR/CR:IR as stated in the claims (%percent Example 2+3+1).
  • a population of minicapsules from Example 2, Example 3 and Example 1 in varying ratio's as stated herein below were removed and blended in a suitable mechanical blender. The blended components were then filled into hard gelatine capsule to the required target strength.
  • Example 2 (50%) + Example 3 (30%) + Example 1 (20%)
  • Example 2 (30%) + Example 3 (60%) + Example 1 (10%)
  • a multiparticulate drag layering process or technique may be used to compliment in combination with the invention. This process or technique is an art that is widely used and is accessible to a variety of formulators in the drag delivery arena.
  • the layering process involves applying an active ingredient and/or excipients onto an inert core e.g. non-pareils using a coating pan or fluid bed coater with a solution/suspension.
  • an inert core e.g. non-pareils
  • the solution/suspension can contain both active ingredient and the binder which is then sprayed onto the inert cores.
  • the other method of layering is the active is directly applied in a powder form by gravity or by auger feeder and adhesion to the inert cores is ensured by spraying a liquid binder onto the inert cores.
  • a further layering method is the inert core is substituted with a active sphere or granule with a particle size in the range of 0.5 - 1.5 mm and the layering process is carried out by spraying or dry powder layering as described above.
  • WO 95/14460 and WO 96/01621 are examples that describe different layering processes.
  • Multiparticulate layering processes using a spherical inert core such as non-pareils in most instances produce a homogeneous drug loaded particle with a spherical shape.
  • Multiparticulate layered spheres produced here can be used in combination with the current invention to achieve the desired dissolution profile for a specific product.
  • the above example was produced by the multiparticulate layering process.
  • This drug layering process is a well known and widely used technique in the drag delivery industry and is regularly used by formulation scientist to develop new delivery systems.
  • the Nimodipine Applied Beads (IR) were manufactured as follows. Nimodipine, Fumaric Acid or Citric Acid or both, talc and sodium lauryl sulphate (active blend) were blended in a suitable Y-Cone blender. The active blend was applied using a suitable fluid bed system onto non-pareils using a suitable binder or adhering solution, such as Povidone from a suitable organic or aqueous solution such as isopropyl alcohol. The resultant immediate release beads were dried for approx 24 hours. The dried multiparticulate spheres were then screened and the appropriate fractions retained.
  • the applied beads were then further processed.
  • a coating solution of a 6.25% solution of Eudragit RS (75-95% w/w) and Eudragit RL (5-25% w/w) dissolved in isopropyl alcohol/acetone mix was sprayed onto the applied beads using a suitable fluid bed system.
  • Talc was added simultaneously via a mechanical feeder to prevent agglomeration.
  • the result was a layered applied sphere with a rate-controlling polymer having a pre-determined dissolution profile.
  • the resultant coated spheres (SR) from this example were then blended with a percentage of the applied (IR) spheres.
  • the blended spheres from the above were filled into hard gelatine capsules to a target strength.
  • Example 1+2+3+4 or Example 2+3+4 or Example 3+4 and the like are listed below as examples of the varying combinations that can be produced by removing a partial population of minicapsules from each of the above examples.
  • Example 1 (10%) + Example 2 (30%) + Example 3 (30%) + Example 4 (30%)
  • Example 2 (25%) + Example 3 (25%) + Example 4 (50%)
  • the core solution was pre-treated with an Ultra Centrifugal Mill. 6.
  • the film solution Nimodipine was pre-treated with a High Pressure
  • Eudragit S was used as the polymer coat to provide an enteric coat with 0 drug release of up to 4 hours to the minicapsules, to target the drug release to the GIT and providing a pulsed release profile.
  • Example 6 A percentage of the Enteric Coated Nimodipine minicapsules and a percentage of the coated minicapsules from Example l(as required) and a percentage of the uncoated minicapsules from Example l(as required) were blended as per in Example 1 and filled into suitable gelatin capsules to the target strength.
  • Example 6 A percentage of the Enteric Coated Nimodipine minicapsules and a percentage of the coated minicapsules from Example l(as required) and a percentage of the uncoated minicapsules from Example l(as required) were blended as per in Example 1 and filled into suitable gelatin capsules to the target strength.
  • Example 6 A percentage of the Enteric Coated Nimodipine minicapsules and a percentage of the coated minicapsules from Example l(as required) and a percentage of the uncoated minicapsules from Example l(as required) were blended as per in Example 1 and filled into suitable gelatin capsules to the target strength.
  • Example 6 A percentage of
  • the Nifedipine core solution was pre-treated with an Ultra Centrifugal Mill. 2.
  • the Nifedipine film solution was pre-treated with a High Pressure Homogeniser.
  • Eudragit S was used as the polymer coat to provide an enteric coat with 0 drug release of up to 2-4 hours to the minicapsules, to target the drug release to the GIT and providing a pulsed release profile.
  • Example 7 Purified Water 4000-6000 grams The minicapsules in Example 7 were manufactured according to Examples 1&2 and filled into suitable hard gelatin capsules to the required target strength.
  • Example 6 From Example 6 take a population of Immediate Release (IR) minicapsules. 2. Take a second population of Sustained Release (SR) minicapsules from
  • Nimodipine Multiparticulate Seamless Minicapsules were manufactured according to freund Industrial Co. Ltd US Patent NO. 5,882,680 (Seamless Capsule and Method of Manufacturing Same), as described in the Summary of the Invention Section.
  • This example allows for the inclusion of the active ingredient in the Film Solution (gelatine layer) as also described in the Summary of the Invention Section.
  • a coating solution of 7% ethylcellulose, 0.85% PVP and 1% magnesium stearate was dissolved in an isopropanol/acetone mixture.
  • the solution was then sprayed coated onto the minicapsules using a suitable fluidised bed processor.
  • Talc was used to prevent agglomeration of the minicapsules during the spray coating stage.
  • the coated minicapsules were dried in an environmentally controlled drier at 40-50 deg.C for typically 12-24 hours.
  • a coating solution of 6.25% Eudragit RL (5%w/w) and 6.25% Eudragit RS (95%w/w) dissolved in isopropyl alcohol/acetone mixture was sprayed coated onto the minicapsules using an automated fluidised bed processor. Talc was used to prevent agglomeration of the minicapsules during the spray coating stage.
  • the coated minicapsules were further dried in an environmentally controlled drier at 40-50deg.C for typically 12-24 hours.
  • Nimodipine seamless minicapsules produced in Example 8 were the encapsulated using suitable hard gelatine capsules into typically 30/60/90/120 or 180mg capsules or alternatively formats for rectal, vaginal or nasal administration.
  • Nimodipine is metabolized through the cytochrome P450 system.
  • nimodipine is metabolized through the cytochrome P450 inhibitor, carbamazepine (anticonvulsant), the clinical effectiveness of nimodipine may be increased (Clin Psychopharmacol, 1998, 18, 404-13).
  • a nimodipine SEDDS (Self Emulsifying Drug Delivery System) formulation is prepared with polyoxyl hydrogenated castor oil.
  • a formulation consisting of a modified vegetable oil (e.g., polyoxyl hydrogenated castor oil), a surfactant (e.g., TPGS), a co-solvent (e.g., propylene glycol) and a bile salt (e.g., sodium deoxycholate) is prepared by successive addition and mixing of each component.
  • the nimodipine is then added to the formulation, which is thoroughly mixed to form a clear homogenous mixture.
  • the carbamazepine is finally added and dissolved quickly under mild agitation.
  • the nimodipine/carbamazepine pre- microemulsion concentrate is then formed into seamless microcapsules according to the methods described in US Pat. Nos. 5, 478,508 and 5,882,680 with an intermediate oil layer and an outer gelatin shell.
  • the formulation for the intermediate oil layer and outer gelatin shell are the same as that outlined in Example 1.
  • Sustained release nimodipine/carbamazepine minicapsules may also be formulated by coating the seamless minicapsules (described in Example 10), with the rate- controlling polymer coat comprised Eudragit RS and Eudragit RL.
  • the formulation and coating procedure for the Eudragit RL (5% w/w) and Eudragit RS (95% w/w) is the same as that outlined in Example 1.
  • Example 11 Another anticonvulsant, valproic acid, has also been shown to inhibit the presystemic oxidative metabolism of nimodipine, resulting in increased plasma concentrations of nimodipine when the two drugs are administered in combination (Drugs Aging, 1995, 6, 229-42).
  • a nimodipine/valproic acid SEDDS (Self Emulsifying Drug Delivery System) formulation is prepared with polyoxyl hydrogenated castor oil as described in Example 10 above, with the valproic acid replacing the carbamazepine in the formulation.
  • the nimodipine/valproic minicapsules may be coated with a Eudragit RS and Eudragit RL polymer coat as described in Example 1.
  • the antihistamine, cimetidine has also been shown to produce an approximate doubling of the bioavailability of nimodipine, as a result of the known inhibitory effect of cimetidine on cytochrome P450 (Drugs Aging, 1995, 6, 229-42).
  • a nimodipine/ cimetidine SEDDS (Self Emulsifying Drug Delivery System) formulation is prepared with polyoxyl hydrogenated castor oil as described in Example 10 above, with the cimetidine replacing the carbamazepine in the formulation.
  • the nimodipine/ cimetidine minicapsules may be coated with a Eudragit RS and Eudragit RL polymer coat as described in Example 10a.
  • the risk of cardiovascular disease can be reduced by treating all the risk factors simultaneously.
  • the risk factors include; LDL cholesterol (treated with simvastatin), blood pressure (treated with ACE inhibitor ramipril, the diuretic hydrochloridethiazide or the calcium channel blocker nimodipine), irregular heart beat (treated with the beta blocker atenolol), serum homocysteine (treated with folic acid), and platelet function (treated with the anticoagulant aspirin).
  • Simvastatin, coenzyme QlO, ramipril, hydrochlorothiazide, nimodipine, and atenolol minicapusles are prepared by solubilising/suspending the actives in a suitable medium chain triglyceride (MCT) and forming into seamless microcapsules with an outer gelatin coating according to the methods described in US Pat. Nos. 5, 478,508 and 5,882,680.
  • MCT medium chain triglyceride
  • minicapsules can also be formulated to include required concentrations of aspirin and folic acid either in the core or in the outer gelatin shell. In cases where the drug loadings required are particularly high, extra pharmaceutical active can also be incorporated into the shell.
  • the formulation of the core formulations for the simvastatin, ramipril and co-enzyme QlO below.
  • the populations of minicapsule can also be coated with a sustained release polymer as described in Example 1 Oa.
  • Simvastatin Core Formulation Ingredients % w/w
  • Hydrochlorothiazide Core Formulation Ingredients % w/w
  • Nimodipine Core Formulation Ingredients % w/w
  • Atenolol Core Formulation Ingredients % w/w
  • Computer generated simulations are used to predict the absorption of a drug when dosed in humans or animals.
  • This software program can be used as a tool to theoretically predict the dissolution profile of a specific drug when designing a drug formulation. Thus, this prediction can theoretically predict the in- vivo profile of the specific drug.
  • WinNonlin ® Professional Edition Version 4.0.1 was utilized to undertake compartmental modelling and pharmacokinetic simulation of mean nimodipine plasma concentration versus time data.
  • WinNonlin is a powerful program for the solution of nonlinear regression problems, constrained estimation problems, systems of differential equations, and mixtures of differential equations and functions.
  • WinNonlin has quickly become the new industry standard in PK, PD, and Noncompartmental Analysis.
  • the source data was derived from a study conducted by Gualano and co-workers at the Aster clinical research organization in Paris, France. Gualano and co-workers evaluated two formulations of nimodipine in a randomised four- way crossover replicate design study.
  • TRRT and RTTR 4-period/2-sequence design
  • Figures 5 to 8 simulate the administration of a 60mg, 120mg or 180mg single dose of nimodipine over the ten ⁇ fold range of Ka values (0.5018 - 5.01 ⁇ hr "1 ) for a period of 4 hours post-dosing.
  • the predicted steady state PK parameters show that the lowest degree of fluctuation occurs following administration of 180mg KO ⁇ 0.7525If 1 BID administration.
  • the average concentrations were comparable across the range (9 - 14 ng/mL).
  • the duration at which the plasma concentration levels remained in excess of 10ug/L was
  • minicapsules When minicapsules are inserted into hard gelatine capsules, depending on the minicapsule size, a vacuum or interstitial or inter-minicapsule space exists. This space may be filled with various liquids, semi-liquids, powders or gases containing various active or inert entities, including drugs, excipients and preservatives.
  • the filling material may be blended with minicapsules prior to filling hard gelatine capsules with the blended liquid, powder or gas.
  • minicapsules also may be blended with various excipients and/or actives prior to being pressed into tablet, pellet or pill formats that may further be coated with various controlled release polymers. Additionally, such pill formats may erode over time permitting controlled release of the minicapsules.
  • the tablet, pellet or pill format may be gastric retentive and swell in the stomach, preventing passage into the small intestine, thus releasing the minicapsule contents at various rates within the stomach.
  • the minicapsules may contain various additional ingredients and/or may be formulated as described in our two co-pending PCT applications filed September 27, 2005 and entitled “Combination Products” and “Minicapsule Formulations", the entire contents of which are herein incorporated by reference.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical formulation comprises a plurality of seamless minicapsules having a diameter of from 0.5 mm to 5 mm, the minicapsules having an encapsulating medium, and the mincapsules containing a dihydropyrimidine such as Nimodipine as an active ingredient.

Description

"Dihydropyrimidine Formulations"
Field Of The Invention
This invention relates to a dosage form of a dihydropyrimidine such as nimodipine.
Background of the Invention
Nimodipine belongs to the class of pharmacological agents known as calcium channel blockers. The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarisation as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. Nimodipine is a yellow crystalline substance, practically insoluble in water. Nimodipine is typically formulated as soft gelatin capsule for oral administration. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition. The precise mode of action is not clear.
Nimodipine is a poorly water soluble drug. Drugs that are poorly water soluble must be formulated in a way that improves their solubility and hence their bioavailability. In general, a drug that is in solution or suspension when administered by the oral route is rapidly and frequently instantaneously absorbed from the gastrointestinal tract resulting in a fast therapeutic action. However in many cases it is desirable to control the rate of absorption following oral administration in order to achieve the desired plasma profile or prolongation of action of the drug.
Furthermore, there is a need for a formulation which will allow practitioners to more easily administer nimodipine formulations especially to traumatised patients within the ICU environment. In the ICU context, prior to administration nimodipine formulations may be mixed with soft foods or liquids and administered to patients via tubing directly to the stomach or small intestine.
Statements of Invention
According to the invention there is provided a pharmaceutical formulation comprising a plurality of seamless minicapsules having a diameter of from 0.5 mm to 5 mm, the minicapsules having an encapsulating medium, and the mincapsules containing a dihydropyrimidine as an active ingredient.
In one embodiment the active ingredient is dispersed in the encapsulating medium.
In one embodiment at least some of the minicapsules comprise a core containing the active ingredient. In at least some of the minicapsules the active ingredient in the core may be solubilised in a pharmaceutically acceptable solvent and/or in a liquid phase. In at least some of the minicapsules the active ingredient may be in a solid form and/or in a semi-solid form.
The minicapsules may have a diameter of from 0.5 mm to 3.0 mm, from 1.2 mm to 2.0 mm, 1.4 mm to 1.8 mm.
In one embodiment at least some of the minicapsules have at least one coating to control the time and/or location of the release of the active entity. At least one coating may be an immediate release coating. At least one coating may be a sustained release coating. The coating may comprise a sustained release and an immediate release coating. At least one coating may be an enteric coating.
In one embodiment the rate-controlling coating is of a polymeric material. The rate-controlling coating may comprise amino methacrylate polymeric material. The rate-controlling coating may be an acrylate and/or methacrylate copolymer with quaternary ammonium.
In one embodiment the coating comprises two copolymers, one of which is highly permeable and the other of which is poorly permeable. The weight ratio of highly permeable polymer to poorly permeable polymer may be from 5:95 to 15:85. The ratio may be from 10:90 to 15:85.
In one case the highly permeable copolymer is applied in the form of a polymer solution. The highly permeable copolymer may be insoluble in water. In one case the poorly permeable copolymer is applied in the form of a polymer solution. The poorly permeable copolymer may be insoluble in water.
In one embodiment the rate-controlling polymer coating contains methacrylate copolymer in the following ratio's 5:95; 10:90; 15:85 (w/w) as a mixture of
Eudragit RL:Eudragit RS.
The copolymer mixture may comprise Eudragit RL 30D:Eudragit RS 30D. The copolymer mixture may comprise Eudragit RL 12.5:Eudragit RS 12.5.
The coating comprises an enteric coating of a methacrylate polymer. The enteric coating may comprise Eudragit S 12.5 or Eudragit SlOO providing 0 drug release in the stomach for up to 4 hours.
In one case at least some of the minicapsules are coated with an immediate release coating. The immediate release coating may be applied to a rate controlling coating. In one embodiment the immediate release coating contains a pharmaceutically active ingredient. An immediate release pharmaceutically active ingredient solution may be applied to a rate-controlling coating. In one embodiment the active pharmaceutical ingredient is suspended or dissolved in the encapsulating medium of the seamless minicapsule. The encapsulating medium may be of one or more of gelatine, agar, a polyethylene glycol, starch, casein, chitosan, soya bean protein, safflower protein, alginates, gellan gum, carrageenan, xanthan gum, phtalated gelatine, succinated gelatine, cellulosephtalate-acetate, oleoresin, polyvinylacetate, hydroxypropyl methyl cellulose, polymerisates of acrylic or methacrylic esters, polyvinylacetate- phtalate and combinations thereof.
In one case the active ingredient is suspended or dissolved in the encapsulating medium. The active ingredient may be micronised or nanonised. In this case the active ingredient may have a particle size of less than 100 microns.
In another embodiment at least some of the minicapsules comprise a core containing micronised or nanonised active ingredient and the encapsulating medium contains micronised or nanonoised active pharmaceutical ingredient suspended or dissolved in the encapsulating medium to enhance the potency of the seamless minicapsules.
A permeability enhancing agent may be suspended or dissolved in the encapsulating medium to enhance active bioavailability.
In one embodiment the formulation comprises a buffer layer.
In another embodiment at least some of the minicapsules are provided with or contain a bioadhesive, typically a mucoadhesive.
In one case the bioadhesive comprises from 0% to 10% by weight of one or more of the following polymer classes:- polyacrylates; polyanhydrides; chitosans; carbopols; cellulose; methylcellulose; methylated deoxycellulose (m- doc™); lectins. The bioadhesive may comprise from 0% to 10% by weight of one or more of the following thiolated or otherwise derivatised polymers:- polyacrylates; polyanhydrides; chitosans; carbopols; cellulose; methylcellulose; methylated deoxycellulose (m-doc™); lectins.
In one case the bioadhesive comprises a coating. Alternatively or additionally the bioadhesive is incorporated into a part or layer of the minicapsule such as rate-controlling layer and/or the encapsulating medium.
In one embodiment at least some of the minicapsules have a layer such as an outer layer which is divided into at least two parts. The parts may have the same or different compositions.
In one embodiment the formulation comprises at least two populations of sustained release minicapsules. The populations may have different in-vitro dissolution profiles.
In another aspect the invention provides a formulation of a dihydropyrimidine as the active ingerdient comprising a plurality of seamless minicapsules having at least two populations selected from:-
a first minicapsule population in which the minicapsules comprise a core containing the active ingredient and an encapsulating medium, the minicapsules having a diameter of from 0.5 mm to 5 mm;
a second minicapsule population in which the minicapsules comprise a plurality of particles containing the active entity dispersed in an encapsulating medium, the minicapsules having a diameter of from 0.5 mm to 5 mm; and a third micro or mini particles population in which the minicapsules comprise an inert core and at least one layer around the core, the layer containing the active ingredient.
In one embodiment the dihydropyridine is nimodipine.
The dihydropyridine may be selected from felodipine, nicardipine nifedipine, istradipine, amlodipine and nisoldipine.
In one case at least some of the minicapsules comprise a core containing nimodipine. The formulation may comprise an immediate release coating which contains nimodipine.
In one embodiment the coating comprises a rate-controlling coating to achieve therapeutically effective plasma levels of the active ingredient over at least 12 hours in a human patient.
The coating may comprise a rate-controlling coating to achieve therapeutically effective plasma levels of the active ingredient over at least 24 hours in a human patient.
In one case the formulation provides a dissolution profile in a pre-determined media such that NMT 25% of the solubilised pharmaceutical active ingredient is released after 1 hour, NMT 40% after 4 hours, NMT 70% after 8 hours and 75 to 100% after 12 hours.
In another case the formulation provides a dissolution profile in pre-determined media such that 10 to 15% of the solubilised pharmaceutical active ingredient is released after 1 hour, about 15 to 30% is released after 4 hours, about 35 to 50% is released after 9 hours, about 45 to 65% is released after 12 hours and at least
80% is released after 24 hours. In one embodiment an enteric coated minicapsule is combined with two sustained release coated minicapsules to provide a pulsed release dissolution profile.
In one case greater than 80% (w/w by potency) of the formulation is comprised of sustained release minicapsules.
In one embodiment the minicapsules provide extended residence times in the small intestine for a period of at least 5 hours, preferably at least 7 hours and more preferably in the 8-24 hours range to enable maximal bioactivity of the core active, locally or systemically.
The minicapsules may provide extended residence times in the nasal passage to enable maximal bioactivity of the core active agent, locally or systemically.
The minicapsules may provide extended residence times in the rectal passage to enable maximal bioactivity of the core active agent, locally or systemically.
The minicapsules may be capable of extended residence times in the vagina or intrauterine to enable maximal bioactivity of the core agent, locally or systemically.
In one embodiment the minicapsules are filled into hard gelatin capsules.
The minicapsules may be filled into a sachet.
The minicapsules may be suspended in oil as a lubricant.
The minicapsules may be contained within a wide gauge syringe that is compatible with tube delivery. The minicapsules may be in the form of a sprinkle.
The minicapsules may be formulated as a suppository for rectal or vaginal or intrauterine administration.
The minicapsules may be formulated for nasal administration.
In one embodiment the formulation contains at least one further active entity. The further active entity may be a P-gp/P450 inhibitor. The further active entity may be carbamazepine, valproic acid, cimetidine or a tryptan such as sumatriptan. The formulation may be for treatment of Alzheimers disease wherein the further active entity comprises a cholinesterase inhibitor (such as donepezil, rivastigmine, galantamine) and one or more from the following classes: vitamins, statins, estrogen, nootrophic agents, ginkgo biloba, anti¬ inflammatory agents, anti-depressants, anti-psychotics, and mood stabilizers.
The further active entity may be selected from one or more of a statin, a thiazidediuretic, a beta blocker, an ACE inhibitor, folic acid, co-enzyme QlO, and an anticoagulant.
In one case the further active entity is present in a seamless minicapsule. The further active entity may be present in at least some of the seamless minicapsules.
The invention also provides a formulation comprising a capsule containing a plurality of minicapsules of the invention.
The capsule may contain another entity.
The other entity may be in a powder, liquid, solid, semi-solid or gaseous form. The other entity may be an active entity.
In another embodiment the formulation comprises a tablet or pellet containing a plurality of minicapsules. The tablet or pellet may contain another entity. The other entity may be an active entity.
The invention provides a controlled release technology which will allow the delivery of a dihydropyrimidine in solution to the optimum site of absorption/action in the gastrointestinal tract.
The dihydropyrimidine formulations of the invention will allow practitioners to more easily administer active pharmaceutical formulations especially to traumatised patients within the ICU environment. In the ICU context, prior to administration of the formulations may be mixed with soft foods or liquids and administered to patients via tubing directly to the stomach or small intestine.
In one embodiment the rate-controlling polymer coat contains Methacrylate Copolymer as described in USP/NF in the following ratio's 5:95; 10:90; 15:85 as a mixture of Eudragit RL: Eudragit RS more especially Eudragit RL 12.5:Eudragit RS
12.5 or Eudragit RL30D: Eudragit RS30D or Eudragit ElOO or Eudragit E PO or a combination thereof.
In another embodiment the rate-controlling polymer coat is an Enteric Coat of Eudragit S 12.5 or Eudragit LlOO or Eudragit SlOO or Eudragit 30D or a combination thereof providing 0 drug release in the stomach for up to 4 hours.
In a further embodiment an enteric coated pharmaceutical active ingredient minicapsule is combined with two SR coated pharmaceutical active ingredient minicapsules components to give Pulsed Release dissolution profile. Brief Description of the Drawings:
The invention will be more clearly understood from the following description thereof given by way of example only with reference to the accompanying drawings, in which: -
Figures 1 to 3 are graphs representing nimodipine multiparticulate seamless minicapsule dissolution profiles;
Figure 1 : Example 1 (Batch MYI l) Nimodipine Multiparticulate
Minicapsule - Immediate Release Dissolution Data (IR) Figure 2: Example 2 (Batch MY21) Nimodipine Multiparticulate
Minicapsule - Sustained/Controlled Release Dissolution
Data (SR/CR) Figure 3: Example 3 (Batch MY22) Nimodipine Multiparticulate
Minicapsule - Sustained/Controlled Release Dissolution
Data (SR/CR).
Figures 4 to 10 are graphs which illustrate the impact of different release rates of nimodipine on % percent release - first order release;
Figure 4: Percent Release versus Time Profile - First Order Release Figure 5: Simulated Single Dose Plasma Concentration versus Time
Profiles (0-4h) - First Order Release (Dose = 60mg) Figure 6: Simulated Single Dose Plasma Concentration versus Time
Profiles (0-4h) - First Order Release (Dose = 120mg) Figure 7: Simulated Single Dose Plasma Concentration versus Time
Profiles (0-4h) - First Order Release (Dose = 180mg) Figure 8: Simulated Single Dose Plasma Concentration versus Time Profiles (0-4h) - First Order Release (KOl = 0.7525;Dose =
180mg) Figure 9: Simulated Steady State Plasma Concentration versus Time Profiles (0-24h) - First Order Release (KOl = 0.7525; Dose 180mg BID and KOl = 5.018; 60mg QID)
Figure 10: Simulated Steady State Plasma Concentration versus Time Profiles (0-24h) - First Order Release (KOl = 0.7525;
Dose 180mg BID and KOl = 5.018; Dose 90mg QID)
Detailed Description
The invention will be more clearly understood from the following description thereof given by way of example only.
The invention provides a multiparticulate seamless minicapsule formulation of a dihydropyrimidine for twice or once daily administration to a patient, comprising sustained release particles each having a core containing a solubilised pharmaceutical active ingredient in a solvent or liquid phase as a seamless minicapsule, the core being coated with a rate-controlling polymer coat comprised of ammonia methacrylate copolymers in an amount sufficient to achieve therapeutically effective plasma levels of the active ingredient over at least 12 or 24 hours.
The pharmaceutical active seamless minicapsules were manufactured according to Freund Industrial Co3 Ltd. US Patent No 5,882,680 (Seamless Capsule and Method of Manufacturing the Same), the entire contents of which are incorporated herein by reference.
The principle of seamless minicapsule formation is the utilisation of "surface tension", when two different solutions (which are not or hardly dissolved with each other) contact each other, which works by reducing the contact area of the two different solutions. After encapsulating the core solution which is ejected through an orifice with a certain diameter, with the shell solution which is also ejected through an outer orifice, the encapsulated sphere is then ejected into a cooling or hardening solution and the outer shell solution is gelled or solidified. This briefly describes the formation of seamless minicapsules.
The core solution is mainly a hydrophobic solution or suspension. The outer shell solution is normally gelatin based. However a hydrophilic solution can also be encapsulated with the existence of an intermediate solution, which can avoid the direct contact of the hydrophilic core solution with the outer shell.
With the nozzle having a single orifice, a minicapsule or a bead of shell/core mixed suspension can be processed.
With the nozzle having two orifices (centre and outer), a hydrophobic solution can be encapsulated.
With the nozzle having three or more orifices seamless minicapsules for various applications can be processed. (Ref US Patent No.5, 882,680)
By using the above described manufacturing processing method as per US patent No.5, 882,680 for multiparticulate seamless minicapsules, active pharmaceutical multiparticulate seamless minicapsules were produced. The completed seamless minicapsules preferably have an average diameter of 0.5 - 3.00mm, more especially in the range 1.50 -1.80mm.
According to one embodiment a portion or all of the sustained release particles further comprise an immediate release coating applied onto the rate-controlling polymer coat, which immediate release coating comprising a solubilised pharmaceutical active ingredient in a liquid phase. In an alternative embodiment, the formulation can contain a portion of immediate release minicapsules each comprising a core of solubilised active pharmaceutical ingredient in a liquid phase.
The formulation according to the invention may also comprise at least two populations of sustained release seamless minicapsules having two different in vitro dissolution profiles.
Also preferably, the formulation according to the invention provides a dissolution profile in a pre-selected media such that about NMT 25% of the solubilised active ingredient is released after 1 hour; NMT 40% after 4 hours; NMT 70% after 8 hours; 75 to 100% after 12 hours.
In an alternative embodiment the formulation provides a dissolution profile in a pre- determined media such that about 10 to 15% of the solubilised active ingredient is released after 1 hour; 15 to 30% is released after 4 hours; about 35 to 50% is release after 9 hours; about 45 to 65% is released after 12 hours and at least 80% is released after 24 hours.
Also, in a preferred embodiment greater than 80% (w/w by potency) of the formulation is comprised of sustained release seamless minicapsules.
In a preferred embodiment the rate-controlling polymer coat contains Ammonia Methacrylate Copolymer Type A and Ammonia Methacrylate Copolymer Type B as described in USP/NF.
Such copolymers are manufactured and marketed by Degussa (Rohm) GmbH, Darmstadt, Germany. Most preferably the rate-controlling polymer coat contains a 5:95 or 10:90 or 15:85 mixture of Eudragit RL: Eudragit RS most especially Eudragit RL30D: Eudragit RS30D or Eudragit RL 12.5:Eudragit RS 12.5
Preferably the sustained release seamless minicapsules following application of the rate-controlling polymer coat are dried at a temperature of about 40-50 deg C, typically for up to 24 hours.
In a preferred embodiment the formulation is encapsulated, for example in a hard gelatin capsule.
The sustained release seamless minicapsules are formed by coating the active seamless minicapsule with the rate-controlling polymer coat comprised of ammonio methacrylate copolymers such as those sold under the Trade Mark EUDRAGIT.
EUDRAGIT polymers are polymeric lacquer substances based on acrylates and/or methacrylates. The polymeric materials sold under the Trade Mark EUDRAGIT RL and EUDRAGIT RS are acrylic resins comprising copolymers of acrylic and methacrylic acid esthers with a low content of quaternary ammonium groups and are described in the "EUDRAGIT" brochure of Messrs. Degussa (Rohm Pharma) GmbH wherein detailed physical-chemical data of these products are given. The ammonium groups are present as salts and give rise to the permeability of the lacquer films. EUDRAGIT RL is freely permeable or RS slightly permeable, independent of pH.
The rate-controlling polymer coat maybe built up by applying a plurality of coats of polymer solution or suspension to the minicapsule as hereafter described. The polymer solution or suspension contains the polymer(s) dissolved or suspended, respectively in a suitable aqueous or organic solvent or mixture of solvents, optionally in the presence of a lubricant. Suitable lubricants are talc, stearic acid, magnesium stearate and sodium stearate. A particularly preferred lubricant is talc. The polymer solution or suspension may optionally include a plasticizing agent. Suitable plasticizing agents include polyethylene glycol, propyleneglycol, glycerol, triacetin, dimethyl phthalate.diethyl phthalate, dibutyl phthalate, dibutyl sebacate or varying percentages of acetylated monoglycerides.
Suitable organic solvents include isopropyl alcohol (IPA) or acetone or a mixture.
The polymer solution or suspension maybe applied to the minicapsules preferably using an automated system such as a GLATT fluidised bed processor, Vector Flow
Coater System or an Aeromatic fluidised bed processor.
Polymer solution/suspension in the quantity of 5-75 ml per kilogram of minicapsules may be applied to the minicapsules using one of the listed automated fluidised bed processing systems to given target polymer coating weight.
In accordance with the invention the drug loaded minicapsules are coated with the rate-controlling polymers to achieve a target dissolution rate. The drug released from these minicapsules is diffusion controlled as the polymer swells and becomes permeable, it allows for the controlled release in the GIT. In order to achieve a suitable dissolution profile, the following parameters require consideration, efficient process/conditions, drug solubility/particle size, minicapsule surface area, minicapsule diameter and coating polymer suitability.
The mucoadhesive controlled GIT transit minicapsules are formed by coating the active seamless minicapsules with the transit-controlling polymer coat comprised of, for example various cellulose or cellulose derivatives such as chitosan or those sold under the brand name Carbopol.
The minicapsule gelatine shell can be modified to comprise a sphere having two hemispheres. Each hemisphere contains variable concentrations of gelatine alone or gelatine in combination with, for example, a mucoadhesive and/or an enteric material. This aspect of the invention will ensure that the active is both in close proximity with the intestinal lumen and protected from intestinal degradative attack.
Nimodipine is a dihydropyridine derivative and belongs to the class of pharmacological agents known as calcium channel blockers. The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarisation as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. Nimodipine is a yellow crystalline substance, practically insoluble in water. Nimodipine is typically formulated as soft gelatine capsules for oral administration. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid haemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition. The precise mode of action is not clear.
The invention provides an oral nimodipine multiparticulate seamless minicapsule formulation for twice or once daily administration to a patient, comprising sustained release particles each having a core containing a solubilised nimodipine in a solvent or liquid phase as a seamless minicapsule, the core being coated with a rate- controlling polymer coat comprised of ammonia methacrylate copolymers in an amount sufficient to achieve therapeutically effective plasma levels of nimodipine over at least 12 or 24 hours.
Example A
Core Solution
--Nimodipine USP/EP 200 grams
--PEG 400 800 grams
Median Solution —Vegetable or Mineral Oil 1000 grams
Film Solution
~ Gelatin 225 grams ~ Sorbitol 25 grams
~ Purified Water 750 grams
Polymer Coating Solution - Eudragit RL 5% w/w -- Eudragit RS 95% w/w
— Talc as required
— Minicapsule diameter 1.50mm
The Nimodipine Multiparticulate Seamless Minicapsules were manufactured according to Freund Industrial Co. Ltd US Patent No. 5,882,680 (Seamless Capsule and Method of Manufacturing Same) and as described in the Summary of the Invention Section.
In order to coat the core solubilised seamless minicapsules, a coating solution of 6.25% Eudragit RL (5% w/w) and Eudragit RS (95% w/w) dissolved in isopropyl alcohol/acetone mixture was sprayed onto the minicapsules using an automated fiuidised bed processor. Talc was added simultaneously to avoid agglomeration.
The coated minicapsules were dried in an environmentally controlled drier for between 12 to 24 hours to remove any residual solvents
Encapsulation 10% immediate release/90% sustained release.
Nimodipine seamless minicapsules uncoated (10% w/w by potency) and the polymer coated minicapsules (90% w/w by potency) from the above were blended using a suitable mechanical blender. The resultant blend was filled into suitable gelatin capsules to the required target strength.
Example B
Core Solution
~ Nimodipine USP/EP 750 grams
— Gelatin 1125 grams
~ Sorbitol 125 grams
~ Purified Water 4250 grams
Polymer Coating solution
- Eudragit RS 85% w/w
— Eudragit RL 5% w/w
~ Dibutyl Sebacate 10% w/w
- Talc as required
~ Minicapsule Diameter 1.50mm
The above seamless minicapsules were manufactured in the same way as Example A with the following exceptions:-
1. The core solution was treated with a High Pressure Homogeniser. The median and film solutions were excluded from this example.
2. The polymer solution included a 10% plasticiser. The Eudragit RS/RL were adjusted proportionately.
3. Two sustained release components were used. SR component 1 was as used in Example A. SR component 2 was what was prepared in Example B which included the plasticiser in the polymer coating solution. The Nimodipine minicapsule uncoated (10-20% w/w by potency), SR 1 (40-45% w/w by potency), SR 2 ( 40-45% w/w by potency) were blended as per Example A and filled into gelatin capsules to the target strength.
Example C
Core Solution
~ Nimodipine USP/EP 500 grams
- Low Viscosity MCT 500 grams
Film Solution ~ Gelatin 590 grams ~ Sorbitol 70 grams
-- Nimodipine USP/EP 340 grams — Purified Water 2290 grams
Polymer Coating Solution
~ Eudragit S
~ Isopropyl Alcohol/acetone as required
- Talc as required
— Minicapsule Diameter 1.50mm
The above seamless minicapsules were manufactured in the same way as Example A with the following exceptions:-
1. The core solution was pre-treated with an Ultra Centrifugal Mill.
2. The film solution Nimodipine, was pre-treated with a High Pressure Homogeniser
3. The median solution was excluded this formulation. 4. Eudragit S was used as the polymer coat to provide an enteric coat with 0 drug release of up to 4 hours to the minicapsules, to target the drug release to the GIT and providing a pulsed release profile.
A percentage of the Enteric Coated Nimodipine minicapsules and a percentage of the coated minicapsules from Example A (as required) and a percentage of the uncoated minicapsules from Example A (as required) were blended as per in Example A and filled into suitable gelatin capsules to the target strength.
Example 1
Core Solution
—Micronised Nimodipine USP/EP 11.7%
-PEG 400 46.6%
Median Solution
~ Medium-Chain Triglycerides (MCT) 2.4% — Sucrose Acetate Isobutylate (SAIB) 9.4%
Film Solution
~ Gelatin 30% ~ Purified Water as required
~ Minicapsule diameter 1.50-1.80 mm
The Immediate Release (IR) Nimodipine Multiparticulate Seamless Minicapsules were manufactured according to Freund Industrial Co. Ltd US Patent No. 5,882,680 (Seamless Capsule and Method of Manufacturing Same) and as described in the Summary of the Invention Section. The multiparticulate minicapsules produced in this example achieved an Immediate Release Dissolution Profile as follows. Dissolution Method
Apparatus: Vankel VK7025 folly auto mated with Gary Win UV
Dissolution Medium: Gastric Juice with 1% SDS pH 1.2 (90OmIs)
Stirring: USP Apparatus 2 (Paddles) at lOOrpm
UV: 330nm
Dissolution Profile of Nimodipine Multiparticulate Immediate Release Seamless Minicapsules Batch MYl 1
Figure imgf000022_0001
This data is graphically presented in Figure 1.
The immediate release product was then filled into hard gelatine capsules to the required dosage strength. Furthermore the invention allows for the immediate release product to be produced in combination with a Sustained Release or Controlled Release multiparticulate minicapsule product in varying ratios of IR:SR/CR. The immediate release minicapsules can be combined with a Sustained or Controlled release minicapsule component in the following ratio's (w/w by potency) e.g. 10% Immediate Release (IR) + 90% Sustained (SR)/Controlled Release (CR) minicapsules; 20% IR + 80% SR/CR; 30% IR + 70% SR/CR; 40% IR + 60% SR/CR and 50% IR + 50% SR/CR.
Example 2 Core Solution
~ Micronised Nimodipine USP/EP 11.7%
~ PEG 400 46.6%
Median Solution - MCT 2.4%
- SAIB 9.4%
Film Solution
~ Gelatin 20.2% ~ Sorbitol 3.0%
~ Hydroxypropylmethyl Cellulose Phthlate (HP55) 6.1%
~ Sodium Hydroxide (NaOH) 0.7%
The above Example 2 were manufactured according to Freund Industrial Co. Ltd US Patent No.5, 882,680 (Seamless Capsule and Method of Manufacturing Same).
In order to control the release (SR) of the Nimodipine over an extended period of time, Hydroxypropylmethyl Cellose Phthalate (HP55) was added to the Film Solution to act as a retarding agent which controlled the release of the Nimodipine over a given period. The multiparticulate minicapsules produced in this example achieved a Sustained/Controlled Release Dissolution Profile as follows.
Dissolution Method
Apparatus: Vankel VK7025 fully auto mated with Cary Win UV Dissolution Medium: Gastric Juice with 1% SDS pH 1.2 (90OmIs)
Stirring: USP Apparatus 2 (Paddles) at lOOrpm
UV: 330nm
Dissolution Profile of Nimodipine Multiparticulate Sustained Release Seamless Minicapsules Batch MY21
Figure imgf000024_0001
This data is graphically presented in Figure 2.
The resultant multiparticulate minicapsules were filled into suitable hard gelatin capsules to the required target strength, typically 30/60/90/120 or 180 mg .Furthermore the invention allows for the combination of the SR/CR multiparticulate minicapsule with an immediate release multiparticulate minicapsule in varying ratio's of SR/CR: IR as stated in the claims (%percent Example 2+1). The IR + SR/CR combination ratio's are as per Example 1.
Example 3
Core Solution
— Micronised Nimodipine USP/EP 37.5% ~ Gelatin 56.3%
~ Sorbitol 6.3%
~ Purified Water as required
Polymer Coating solution
~ Eudragit RS 85% w/w
~ Eudragit RL 5% w/w
~ Dibutyl Sebacate 10% w/w
~ Talc as required
~ Minicapsule Diameter 1.50 1.80mm
The above seamless minicapsules were manufactured in the same way as Example 1&2 with the following exceptions :-
4. The core solution was treated with a High Pressure Homogeniser.
5. The median and film solutions of examples 1 and 2 were excluded from this example.
6; The polymer coating solution included a 10% plasticiser. The Eudragit RS/RL were adjusted proportionately.
The process used to manufacture the multiparticulate minicapsules in this example in principle was the same as used in Example 1 & 2 with the exception that only a single orifice dosing system was used instead of the normal multiple dosing orifice system. By using a single dosing orifice a uniform solid gelatine pellet or sphere is produced to a specified particle size. This method produces a durable sphere in a gelatine format that includes the active ingredient which in turn allows the sphere or multipaticulate pellet to be further processes with various polymer coating systems. The multiparticulate minicapsules produced in this example achieved a Sustained/Controlled Release Dissolution Profile as follows. Dissolution Method
Apparatus: Vankel VK7025 fully auto mated with Cary Win UV
Dissolution Medium: Gastric Juice with 1% SDS pH 1.2 (90OmIs)
Stirring: USP Apparatus 2 (Paddles) at lOOrpm
UV: 330nm
Dissolution Profile of Nimodipine Multiparticulate Sustained Release Seamless Minicapsules Batch MY22
Figure imgf000026_0001
This data is graphically presented in Figure 3.
Furthermore the invention allows for the combination of a SR/CR multiparticulate minicapsule with another SR/CR multiparticulate minicapsule and a IR multiparticulate minicapsule or other combinations thereof in varying ratio's of SR/CR: SR/CR:IR as stated in the claims (%percent Example 2+3+1). A population of minicapsules from Example 2, Example 3 and Example 1 in varying ratio's as stated herein below were removed and blended in a suitable mechanical blender.The blended components were then filled into hard gelatine capsule to the required target strength. Example 2 (45%) + Example 3 (45%) + Example 1 (10%)
Example 2 (50%) + Example 3 (30%) + Example 1 (20%) Example 2 (30%) + Example 3 (60%) + Example 1 (10%)
Drug Layering A multiparticulate drag layering process or technique may be used to compliment in combination with the invention. This process or technique is an art that is widely used and is accessible to a variety of formulators in the drag delivery arena.
This technique is known to be used by a number of companies in their technologies namely Eurand in their DIFFUCAP Technology, Shire - MICROTROL Technology,
KV Pharmaceuticals - KV/24 Technology, Elan - SODAS Technology, to name a few.
The layering process involves applying an active ingredient and/or excipients onto an inert core e.g. non-pareils using a coating pan or fluid bed coater with a solution/suspension. In some instances the solution/suspension can contain both active ingredient and the binder which is then sprayed onto the inert cores. The other method of layering is the active is directly applied in a powder form by gravity or by auger feeder and adhesion to the inert cores is ensured by spraying a liquid binder onto the inert cores.
A further layering method is the inert core is substituted with a active sphere or granule with a particle size in the range of 0.5 - 1.5 mm and the layering process is carried out by spraying or dry powder layering as described above. WO 95/14460 and WO 96/01621 are examples that describe different layering processes.
Multiparticulate layering processes using a spherical inert core such as non-pareils in most instances produce a homogeneous drug loaded particle with a spherical shape.
These spherical shaped particles in turn lend themselves favourably to coating with various polymers to provide a desired drag release profile.
Multiparticulate layered spheres produced here can be used in combination with the current invention to achieve the desired dissolution profile for a specific product.
Example 4
— Micronised Nimodipine USP/EP 500 grams
— Fumaric Acid 0-125 grams -- Citric Acid 0-125 grams
~ Talc 5- 250 grams
~ Sodium Lauryl Sulphate 0.125 grams
— Sugar spheres (Non-Pareils) 250 grams ~ Kollidon 30 (Povidone) 50-150 grams - Eudragit RL 5-15 grams
~ Eudragit RS 35- 50 grams
— Isopropyl Alcohol . as required ~ Acetone as required
— Diameter Multiparticulate Spheres 1.50-1.80 mm
The above example was produced by the multiparticulate layering process. This drug layering process is a well known and widely used technique in the drag delivery industry and is regularly used by formulation scientist to develop new delivery systems. The Nimodipine Applied Beads (IR) were manufactured as follows. Nimodipine, Fumaric Acid or Citric Acid or both, talc and sodium lauryl sulphate (active blend) were blended in a suitable Y-Cone blender. The active blend was applied using a suitable fluid bed system onto non-pareils using a suitable binder or adhering solution, such as Povidone from a suitable organic or aqueous solution such as isopropyl alcohol. The resultant immediate release beads were dried for approx 24 hours. The dried multiparticulate spheres were then screened and the appropriate fractions retained.
The applied beads (IR) were then further processed. A coating solution of a 6.25% solution of Eudragit RS (75-95% w/w) and Eudragit RL (5-25% w/w) dissolved in isopropyl alcohol/acetone mix was sprayed onto the applied beads using a suitable fluid bed system. Talc was added simultaneously via a mechanical feeder to prevent agglomeration. The result was a layered applied sphere with a rate-controlling polymer having a pre-determined dissolution profile.
The resultant coated spheres (SR) from this example were then blended with a percentage of the applied (IR) spheres. The blended spheres from the above were filled into hard gelatine capsules to a target strength.
Furthermore the above example could also be combined with other the examples listed above. The following combinations in varying % percent ratio's can also be produced to give a pre-determined dissolution profile :-
Example 1+2+3+4 or Example 2+3+4 or Example 3+4 and the like. The following ratios are listed below as examples of the varying combinations that can be produced by removing a partial population of minicapsules from each of the above examples.
Example 1 (10%) + Example 2 (30%) + Example 3 (30%) + Example 4 (30%)
Example 2 (25%) + Example 3 (25%) + Example 4 (50%)
Example 3 (50%) + Example 4 (50%)
Example 5
Core Solution ~ Nimodipine USP/EP 500 grams — Low Viscosity MCT 500 grams
Film Solution ~ Gelatin 590 grams
- Sorbitol 70 grams
- Nimodipine USP/EP 340 grams ~ Purified Water 2290 grams
Polymer Coating Solution
- Eudragit S as required
~ Isopropyl Alcohol/acetone as required
~ Talc as required
~ Minicapsule Diameter 1.50-1.80 mm
The above seamless minicapsules were manufactured in the same way as Example 1 with the following exceptions:-
5. The core solution was pre-treated with an Ultra Centrifugal Mill. 6. The film solution Nimodipine, was pre-treated with a High Pressure
Homogeniser
7. The median solution was excluded this formulation.
8. Eudragit S was used as the polymer coat to provide an enteric coat with 0 drug release of up to 4 hours to the minicapsules, to target the drug release to the GIT and providing a pulsed release profile.
A percentage of the Enteric Coated Nimodipine minicapsules and a percentage of the coated minicapsules from Example l(as required) and a percentage of the uncoated minicapsules from Example l(as required) were blended as per in Example 1 and filled into suitable gelatin capsules to the target strength. Example 6
Core Solution
- Nifedipine USP/EP 100-400 grams
-- PEG 400 400-800 grams
Median Solution
~ Low Viscosity MCT 500-1000 grams
Film Solution ~ Gelatin 590 grams
- Sorbitol 70 grams
- Nifedipine USP/EP 100-400 grams ~ Purified Water 1000-2500 grams
Polymer Coating Solution
— Eudragir S as required
~ Isopropyl Alcohol/ Acetone as required ~ Talc as required
— Minicapsule Diameter 1.50-1.80 mm
The above seamless minicapsules were manufactured in the same way as Example 1 with the following exceptions: -
1. The Nifedipine core solution was pre-treated with an Ultra Centrifugal Mill. 2. The Nifedipine film solution, was pre-treated with a High Pressure Homogeniser.
3. Eudragit S was used as the polymer coat to provide an enteric coat with 0 drug release of up to 2-4 hours to the minicapsules, to target the drug release to the GIT and providing a pulsed release profile.
Example 7
Core Solution -- Micronised Nifedipine 500-1000 grams
— Gelatin 500-3000 grams
~ Sorbitol 0-200 grams
~ Purified Water 4000-6000 grams The minicapsules in Example 7 were manufactured according to Examples 1&2 and filled into suitable hard gelatin capsules to the required target strength.
Example 8
1. From Example 6 take a population of Immediate Release (IR) minicapsules. 2. Take a second population of Sustained Release (SR) minicapsules from
Example 6
3. In the following ratio 5-25% Immediate Release (IR) and 75-95% Sustained Release (SR) minicapsules calculated by potency from Example 6 are blended using a suitable blender and encapsulated using suitable hard gelatin capsules into the target strengths.
Example 9
Core Solution
~ Micronised Nimodipine USP/EP 100-400 grams
~ PEG 400 400-800 grams
Median Solution Vegetable Oil or Mineral Oil 0-1000 grams
Mucoadhesive Coating Solution
— Ethycellulose 5-100 grams
- PVP 0.5-50 grams
~ Castor Oil 0-50 grams
~ Magnesium Stearate 0-50 grams ~ Acetone as required
~ Isopropanol as required Film Solution
— Gelatin 100-500 grams
~ Sumatriptan 0-100 grams ~ Sorbitol 0-50 grams
— Purified water 500- 3000 grams
Polymer Coating Solution
— Eudragit RL 5% w/w
~ Eudragit RS 95% w/w
~ Isopropyl Alcohol as required
~ Acetone as required
~ Talc as required
-- Minicapsule Diameter 0.5-1.80mm
The Nimodipine Multiparticulate Seamless Minicapsules were manufactured according to freund Industrial Co. Ltd US Patent NO. 5,882,680 (Seamless Capsule and Method of Manufacturing Same), as described in the Summary of the Invention Section. This example allows for the inclusion of the active ingredient in the Film Solution (gelatine layer) as also described in the Summary of the Invention Section.
To apply a mucoadhesive coating, a coating solution of 7% ethylcellulose, 0.85% PVP and 1% magnesium stearate was dissolved in an isopropanol/acetone mixture. The solution was then sprayed coated onto the minicapsules using a suitable fluidised bed processor. Talc was used to prevent agglomeration of the minicapsules during the spray coating stage. The coated minicapsules were dried in an environmentally controlled drier at 40-50 deg.C for typically 12-24 hours.
In order to further coat the mucoadhesive coated seamless minicapsules, a coating solution of 6.25% Eudragit RL (5%w/w) and 6.25% Eudragit RS (95%w/w) dissolved in isopropyl alcohol/acetone mixture was sprayed coated onto the minicapsules using an automated fluidised bed processor. Talc was used to prevent agglomeration of the minicapsules during the spray coating stage. The coated minicapsules were further dried in an environmentally controlled drier at 40-50deg.C for typically 12-24 hours.
The Nimodipine seamless minicapsules produced in Example 8 were the encapsulated using suitable hard gelatine capsules into typically 30/60/90/120 or 180mg capsules or alternatively formats for rectal, vaginal or nasal administration.
Combination of nimodipine and P-gp/P4S0 inhibitors
Example 10
Nimodipine is metabolized through the cytochrome P450 system. By combining nimodipine with the cytochrome P450 inhibitor, carbamazepine (anticonvulsant), the clinical effectiveness of nimodipine may be increased (Clin Psychopharmacol, 1998, 18, 404-13). A nimodipine SEDDS (Self Emulsifying Drug Delivery System) formulation is prepared with polyoxyl hydrogenated castor oil. A formulation consisting of a modified vegetable oil (e.g., polyoxyl hydrogenated castor oil), a surfactant (e.g., TPGS), a co-solvent (e.g., propylene glycol) and a bile salt (e.g., sodium deoxycholate) is prepared by successive addition and mixing of each component. The nimodipine is then added to the formulation, which is thoroughly mixed to form a clear homogenous mixture. The carbamazepine is finally added and dissolved quickly under mild agitation. The nimodipine/carbamazepine pre- microemulsion concentrate is then formed into seamless microcapsules according to the methods described in US Pat. Nos. 5, 478,508 and 5,882,680 with an intermediate oil layer and an outer gelatin shell. The formulation for the intermediate oil layer and outer gelatin shell are the same as that outlined in Example 1.
Core Formulation
Ingredients % wΛv Nimodipine 2.5-5 Carbamazepine 2.5
Unconjugated deoxycholic acid 5
Fractionated oat oil 30
Cremophor EL or TPGS 30 PEG 400 30
Example IQa
Sustained release nimodipine/carbamazepine minicapsules may also be formulated by coating the seamless minicapsules (described in Example 10), with the rate- controlling polymer coat comprised Eudragit RS and Eudragit RL. The formulation and coating procedure for the Eudragit RL (5% w/w) and Eudragit RS (95% w/w) is the same as that outlined in Example 1.
Example 11 Another anticonvulsant, valproic acid, has also been shown to inhibit the presystemic oxidative metabolism of nimodipine, resulting in increased plasma concentrations of nimodipine when the two drugs are administered in combination (Drugs Aging, 1995, 6, 229-42).
A nimodipine/valproic acid SEDDS (Self Emulsifying Drug Delivery System) formulation is prepared with polyoxyl hydrogenated castor oil as described in Example 10 above, with the valproic acid replacing the carbamazepine in the formulation. The nimodipine/valproic minicapsules may be coated with a Eudragit RS and Eudragit RL polymer coat as described in Example 1.
Example 12
The antihistamine, cimetidine, has also been shown to produce an approximate doubling of the bioavailability of nimodipine, as a result of the known inhibitory effect of cimetidine on cytochrome P450 (Drugs Aging, 1995, 6, 229-42). A nimodipine/ cimetidine SEDDS (Self Emulsifying Drug Delivery System) formulation is prepared with polyoxyl hydrogenated castor oil as described in Example 10 above, with the cimetidine replacing the carbamazepine in the formulation. The nimodipine/ cimetidine minicapsules may be coated with a Eudragit RS and Eudragit RL polymer coat as described in Example 10a.
Combinations of the statins with thiazide diuretics, beta blockers, ACE inhibitors, folic acid, co-enzyme QlO and anticoagulants Example 12 The risk of cardiovascular disease can be reduced by treating all the risk factors simultaneously. The risk factors include; LDL cholesterol (treated with simvastatin), blood pressure (treated with ACE inhibitor ramipril, the diuretic hydrochloridethiazide or the calcium channel blocker nimodipine), irregular heart beat (treated with the beta blocker atenolol), serum homocysteine (treated with folic acid), and platelet function (treated with the anticoagulant aspirin). For ease of administration and to simplify the CVD prevention treatment regime, it is preferable that some or all of the drugs mentioned above or formulated into a single dosage form. Obviously with the large number of actives involved, it can be difficult to achieve the drug loadings necessary using conventional dosage forms. The increased solubility conferred on the actives using the LEDDS technology can however be used to achieve the desired loadings.
Simvastatin, coenzyme QlO, ramipril, hydrochlorothiazide, nimodipine, and atenolol minicapusles are prepared by solubilising/suspending the actives in a suitable medium chain triglyceride (MCT) and forming into seamless microcapsules with an outer gelatin coating according to the methods described in US Pat. Nos. 5, 478,508 and 5,882,680. These minicapsules can also be formulated to include required concentrations of aspirin and folic acid either in the core or in the outer gelatin shell. In cases where the drug loadings required are particularly high, extra pharmaceutical active can also be incorporated into the shell. The formulation of the core formulations for the simvastatin, ramipril and co-enzyme QlO below. The populations of minicapsule can also be coated with a sustained release polymer as described in Example 1 Oa.
Simvastatin Core Formulation Ingredients % w/w
Simvastatin 10-20
MCT 80-90
Ramipril Core Formulation Ingredients % w/w
Ramipril 10-20
MCT 80-90
Co-enzyme QlO Core Formulation Ingredients % w/w
Co-enzyme QlO 10-20 MCT
Hydrochlorothiazide Core Formulation Ingredients % w/w
Hydrochlorothiazide 10-20
MCT 80-90
Nimodipine Core Formulation Ingredients % w/w
Nimodipine 10-20
MCT 80-90
Atenolol Core Formulation Ingredients % w/w
Atenolol 10-20 MCT 80-90
Shell Solution
Ingredients % w/w Gelatin 15-20
Sorbitol/Glycerin 1-5
Purified Water 70-80
Folic acid 1-5
Aspirin 1-5
In - Vitro / In - Vivo Correlations QVIVQ
Computer generated simulations are used to predict the absorption of a drug when dosed in humans or animals.This software program can be used as a tool to theoretically predict the dissolution profile of a specific drug when designing a drug formulation. Thus, this prediction can theoretically predict the in- vivo profile of the specific drug.
The simulations and the software program is described below.
WinNonlin® Professional Edition Version 4.0.1 (Pharsight Corporation, Cary, USA) was utilized to undertake compartmental modelling and pharmacokinetic simulation of mean nimodipine plasma concentration versus time data. WinNonlin is a powerful program for the solution of nonlinear regression problems, constrained estimation problems, systems of differential equations, and mixtures of differential equations and functions. WinNonlin has quickly become the new industry standard in PK, PD, and Noncompartmental Analysis. The source data was derived from a study conducted by Gualano and co-workers at the Aster clinical research organization in Paris, France. Gualano and co-workers evaluated two formulations of nimodipine in a randomised four- way crossover replicate design study. The study subjects received both Test (two 30mg film-coated Brainal® tablets) and Reference (two 30mg film-coated Nimotop® tablets) treatments as a replicate administration of the two treatments according to a 4-period/2-sequence design (TRRT and RTTR)5 with a washout period of 7 days between each treatment. The study population was twenty-four normal healthy Caucasian male volunteers. The clinical part of the study was carried out using a replicate design in order to minimize the effects due to the high variability in the bioavailability of nimodipine and the high intra-individual variability.
A number of different compartmental models (different number of compartments and with and without associated lag times) were fitted to the available source data.
A two compartmental model with an associated lag time was selected as the most appropriate model to use for simulation purposes and initial estimates were determined. Following fitting of the mean IR data, first order release target profiles were generated for Karel which resulted in 90% release of active over 1 — 5 hours. These target profiles are illustrated in the graph below. These ranges of ka values were deemed suitable and from these in vivo profiles were simulated. It is assumed that the release rate from the formulation (Karel) is the predominant rate constant (compared to the absorption rate constant Ka). A ten-fold range of Ka values (0.5018 - 5.01 δhr"1) were simulated to determine the optimal formulation approach which would maintain plasma concentration levels in excess of the proposed therapeutic target concentration of 30ng/mL for the maximum duration. The impact of this range of Karel values on the % release versus time profiles are presented in Figure 4.
Using the initial estimates determined following the compartmental modelling of the source data, the following simulations were derived. Figures 5 to 8 simulate the administration of a 60mg, 120mg or 180mg single dose of nimodipine over the ten¬ fold range of Ka values (0.5018 - 5.01 δhr"1) for a period of 4 hours post-dosing.
Upon review, an additional KOl value was simulated 0.7527 over a 12h period as the optimal target profile was proposed as lying in the range between KOl 0.5018 and 1.25451Ir"1. The simulated single dose profile with this KOl at a dose level of 180mg is presented in Figure 8.
Steady state projections were then simulated with 180mg nimodipine KOl of 0.7527b"1 following BID dosing compared to a reference of 60mg nimodipine following QID dosing (K01=5.018).
Steady state projections were then simulated with 180mg nimodipine KOl of 0.7527b"1 following BID dosing compared to a reference of 90mg nimodipine following QID dosing (K01=5.018).
The simulated pharmacokinetic parameters following administration of 180mg nimodipine (0^0.7525If1), 60mg or 90mg nimodipine (KOl=S-OlSh'1).
Figure 11 - TABLE I Simulated pharmacokinetic parameters - First Order Release
Figure imgf000040_0001
The predicted steady state PK parameters show that the lowest degree of fluctuation occurs following administration of 180mg KO ^0.7525If1 BID administration. The average concentrations were comparable across the range (9 - 14 ng/mL). The duration at which the plasma concentration levels remained in excess of 10ug/L was
10.6h following administration of 180mg K01=0.7525h'! BID, 7.2h following administration of 60mg K01=5.018h"' and 10.3h following administration of 80mg KOl=S-OlSh"1 Capsule-minicapsule Cavity
When minicapsules are inserted into hard gelatine capsules, depending on the minicapsule size, a vacuum or interstitial or inter-minicapsule space exists. This space may be filled with various liquids, semi-liquids, powders or gases containing various active or inert entities, including drugs, excipients and preservatives. The filling material may be blended with minicapsules prior to filling hard gelatine capsules with the blended liquid, powder or gas.
Pill Format
Apart from insertion into hard gelatine capsules, minicapsules also may be blended with various excipients and/or actives prior to being pressed into tablet, pellet or pill formats that may further be coated with various controlled release polymers. Additionally, such pill formats may erode over time permitting controlled release of the minicapsules.
In a further embodiment, the tablet, pellet or pill format may be gastric retentive and swell in the stomach, preventing passage into the small intestine, thus releasing the minicapsule contents at various rates within the stomach.
The minicapsules may contain various additional ingredients and/or may be formulated as described in our two co-pending PCT applications filed September 27, 2005 and entitled "Combination Products" and "Minicapsule Formulations", the entire contents of which are herein incorporated by reference.
This invention is not limited to the embodiments hereinbefore described which may be varied in detail.

Claims

Claims
1. A pharmaceutical formulation comprising a plurality of seamless minicapsules having a diameter of from 0.5 mm to 5 mm, the minicapsules having an encapsulating medium, and the mincapsules containing a dihydropyrimidine as an active ingredient.
2. A formulation as claimed in claim 1 wherein the active ingredient is dispersed in the encapsulating medium.
3. A formulation as claimed in claim 1 or 2 wherein at least some of the minicapsules comprise a core containing the active ingredient.
4. A formulation as claimed in claim 3 wherein in at least some of the minicapsules the active ingredient in the core is solubilised in a pharmaceutically acceptable solvent and/or in a liquid phase.
5. A formulation as claimed in any of claims 1 to 4 wherein in at least some of the minicapsules the active ingredient is in a solid form and/or in a semi-solid form.
6. A formulation as claimed in any of claims 1 to 5 wherein the minicapsules have a diameter of from 0.5 mm to 3.0 mm.
7. A formulation as claimed in any of claims 1 or 6 wherein the minicapsules have a diameter of from 1.2 mm to 2.0 mm.
8. A formulation as claimed in any of claims 1 to 7 wherein the minicapsules have a diameter of from 1.4 mm to 1.8 mm.
9. A formulation as claimed in any of claims 1 to 8 wherein at least some of the minicapsules have at least one coating to control the time and/or location of the release of the active entity.
10. A formulation as claimed in claim 9 wherein at least one coating is an immediate release coating.
11. A formulation as claimed in claim 9 or 10 wherein at least one coating is a sustained release coating.
12. A formulation as claimed in any of claims 9 to 11 wherein the coating comprises a sustained release and an immediate release coating.
13. A formulation as claimed in any of claims 9 to 12 wherein at least one coating is an enteric coating.
14. A formulation as claimed in any of claims 9 to 13 wherein the rate- controlling coating is of a polymeric material.
15. A formulation as claimed in any of claims 9 to 14 wherein the rate- controlling coating comprises amino methacrylate polymeric material.
16. A formulation as claimed in any of claims 9 to 15 wherein the rate- controlling coating is an acrylate and/or methacrylate copolymer with quaternary ammonium.
17. A formulation as claimed in any of claims 9 to 16 wherein the coating comprises two copolymers, one of which is highly permeable and the other of which is poorly permeable.
18. A formulation as claimed in claim 17 wherein the weight ratio of highly permeable polymer to poorly permeable polymer is from 5:95 to 15:85.
19. A formulation as claimed in claim 18 wherein the ratio is from 10:90 to 15:85.
20. A formulation as claimed in any of claims 17 to 19 wherein the highly permeable copolymer is applied in the form of a polymer solution.
21. A formulation as claimed in claim 20 wherein the highly permeable copolymer is insoluble in water.
22. A formulation as claimed in any of claims 17 to 21 wherein the poorly permeable copolymer is applied in the form of a polymer solution.
23. A formulation as claimed in claim 22 wherein the poorly permeable copolymer is insoluble in water.
24. A formulation as claimed in any of claims 9 to 23 wherein the rate- controlling polymer coating contains methacrylate copolymer in the following ratio's 5:95; 10:90; 15:85 (w/w) as a mixture of Eudragit RL:Eudragit RS.
25. A formulation as claimed in claim 24 wherein the copolymer mixture comprises Eudragit RL 30D:Eudragit RS 30D.
26. A formulation as claimed in claim 24 wherein the copolymer mixture comprises Eudragit RL 12.5:Eudragit RS 12.5.
27. A formulation as claimed in any of claim 9 to 26 wherein the coating comprises an enteric coating of a methacrylate polymer.
28. A formulation as claimed in claim 27 wherein the enteric coating comprises Eudragit S 12.5 or Eudragit SlOO providing 0 drug release in the stomach for up to 4 hours.
29. A formulation as claimed in any of claims 9 to 18 wherein at least some of the minicapsules are coated with an immediate release coating.
30. A formulation as claimed in claim 29 wherein the immediate release coating is applied to a rate controlling coating.
31. A formulation as claimed in claim 29 or 30 wherein the immediate release coating contains a pharmaceutically active ingredient.
32. A formulation as claimed in claims 30 or 31 wherein an immediate release pharmaceutically active ingredient solution is applied to a rate-controlling coating.
33. A formulation according to any of claims 1 to 32 wherein the active pharmaceutical ingredient is suspended or dissolved in the encapsulating medium of the seamless minicapsule.
34. A formulation as claimed in any of claims 1 to 33 wherein the encapsulating medium is of one or more of gelatine, agar, a polyethylene glycol, starch, casein, chitosan, soya bean protein, safflower protein, alginates, gellan gum, carrageenan, xanthan gum, phtalated gelatine, succinated gelatine, cellulosephtalate-acetate, oleoresin, polyvinylacetate, hydroxypropyl methyl cellulose, polymerisates of acrylic or methacrylic esters, polyvinylacetate-phtalate and combinations thereof.
35. A formulation according to claim 34 wherein the active ingredient is suspended or dissolved in the encapsulating medium.
36. A formulation as claimed in any of claims 1 to 35 wherein the active ingredient is micronised or nanonised.
37. A formulation as claimed in claim 36 wherein the active ingedient has a particle size of less than 100 microns.
38. A formulation as claimed in any of claims 1 to 37 wherein at least some of the minicapsules comprise a core containing micronised or nanonised active ingredient and the encapsulating medium contains micronised or nanonoised active pharmaceutical ingredient suspended or dissolved in the encapsulating medium to enhance the potency of the seamless minicapsules.
39. A formulation as claimed in any of claims 1 to 38 wherein a permeability enhancing agent is suspended or dissolved in the encapsulating medium to enhance active bioavailability.
40. A formulation as claimed in any of claims 1 to 39 wherein at least some of the minicapsules comprise a buffer layer.
41. A formulation as claimed in any of claims 1 to 40 wherein at least some of the minicapsules are provided with or contain a bioadhesive such as a mucoadhesive.
42. A formulation as claimed in claim 41 wherein the bioadhesive comprises from 0% to 10% by weight of one or more of the following polymer classes:- polyacrylates; polyanhydrides; chitosans; carbopols; cellulose; methylcellulose; methylated deoxycellulose (m-doc™); lectins.
43. A formulation as claimed in claim 41 wherein the bioadhesive coating comprises from 0% to 10% by weight of one or more of the following thiolated or otherwise derivatised polymers:- polyacrylates; polyanhydrides; chitosans; carbopols; cellulose; methylcellulose; methylated deoxycellulose (m-doc™); lectins.
44. A formulation as claimed in any of claims 41 to 43 wherein the bioadhesive comprises a coating.
45. A formulation as claimed in any of claims 41 to 44 wherein the bioadhesive is incorporated into a part or layer of the minicapsule.
46. A formulation as claimed in claim 45 wherein the bioadhesive is incorporated into a rate-controlling layer.
47. A formulation as claimed in claim 45 or 46 wherein the bioadhesive is incorporated into the encapsulating medium.
48. A formulation as claimed in any of claims 1 to 47 wherein at least some of the minicapsules have a layer such as an outer layer which is divided into at least two parts.
49. A formulation as claimed in claim 48 wherein the parts are of the same composition.
50. A formulation as claimed in claim 48 wherein at least some of the parts have different compositions.
51. A formulation as claimed in any of claims 1 to 50 which comprises at least two populations of sustained release minicapsules.
52. A formulation as claimed in claim 51 wherein the populations have different in- vitro dissolution profiles.
53. A formulation of a dihydropyrimidine as the active ingerdient comprising a plurality of seamless minicapsules having at least two populations selected from:-
a first minicapsule population in which the minicapsules comprise a core containing the active ingredient and an encapsulating medium, the minicapsules having a diameter of from 0.5 mm to 5 mm;
a second minicapsule population in which the minicapsules comprise a plurality of particles containing the active entity dispersed in an encapsulating medium, the minicapsules having a diameter of from 0.5 mm to 5 mm; and
a third micro or mini particles population in which the minicapsules comprise an inert core and at least one layer around the core, the layer containing the active ingredient.
54. A formulation as claimed in any of claims 1 to 53 wherein the dihydropyridine is nimodipine.
55. A formulation as claimed in any of claims 1 to 53 wherein the dihydropyridine is selected from felodipine, nicardipine nifedipine, istradipine, amlodipine and nisoldipine.
56. A formulation as claimed in any of claims 1 to 53 wherein at least some of the minicapsules comprise a core containing nimodipine.
57. A formulation as claimed in any of claims 1 to 53 or 56 wherein the formulation comprises an immediate release coating which contains nimodipine.
58. A formulation as claimed in any of claims 9 to 57 wherein the coating comprises a rate-controlling coating to achieve therapeutically effective plasma levels of the active ingredient over at least 12 hours in a human patient.
59. A formulation as claimed in any of claims 9 to 58 wherein the coating comprises a rate-controlling coating to achieve therapeutically effective plasma levels of the active ingredient over at least 24 hours in a human patient.
60. A formulation as claimed in any of claims 9 to 59 which provides a dissolution profile in a pre-determined media such that NMT 25% of the solubilised pharmaceutical active ingredient is released after 1 hour, NMT 40% after 4 hours, NMT 70% after 8 hours and 75 to 100% after 12 hours, alternatively the formulation provides a dissolution profile in pre¬ determined media such that 10 to 15% of the solubilised pharmaceutical active ingredient is released after 1 hour, about 15 to 30% is released after 4 hours, about 35 to 50% is released after 9 hours, about 45 to 65% is released after 12 hours and at least 80% is released after 24 hours.
61. A formulation as claimed in any of claims 1 to 60 wherein an enteric coated minicapsule is combined with two sustained release coated minicapsules to provide a pulsed release dissolution profile.
62. A formulation as claimed in any of claims 1 to 61 wherein greater than 80% (w/w by potency) of the formulation is comprised of sustained release minicapsules.
63. A formulation as claimed in any of claims 1 to 56 wherein the minicapsules provide extended residence times in the small intestine for a period of at least 5 hours, preferably at least 7 hours and more preferably in the 8-24 hours range to enable maximal bioactivity of the core active, locally or systemically.
64. A formulation as claimed in any of claims 1 to 62 wherein the minicapsules provide extended residence times in the nasal passage to enable maximal bioactivity of the core active agent, locally or systemically.
65. A formulation as claimed in any of claims 1 to 62 wherein the minicapsules provide extended residence times in the rectal passage to enable maximal bioactivity of the core active agent, locally or systemically.
66. A formulation as claimed in any of claims 1 to 62 wherein the minicapsules are capable of extended residence times in the vagina or intrauterine to enable maximal bioactivity of the core agent, locally or systemically.
67. A formulation according to any of claims 1 to 66 wherein the minicapsules are filled into hard gelatin capsules.
68. A formulation according to any of the claims 1 to 66 wherein the minicapsules are filled into a sachet.
69. A formulation according to any of claims 1 to 66 wherein the minicapsules are suspended in oil as a lubricant.
70. A formulation according to any of claims 1 to 66 wherein the minicapsules are contained within a wide gauge syringe that is compatible with tube delivery.
71. A formulation according to any of claims 1 to 66 wherein the minicapsules are in the form of a sprinkle.
72. A formulation according to any of the claims 1 to 66 wherein the minicapsules are formulated as a suppository for rectal or vaginal administration.
13. A formulation according to any of claims 1 to 66 wherein the minicapsules are formulated for nasal administration.
74. A formulation as claimed in any of claims 1 to 73 wherein the formulation contains at least one further active entity.
75. A formulation as claimed in claim 74 wherein the further active entity is a P-gp/P450 inhibitor.
76. A formulation as claimed in claim 74 or 75 wherein the further active entity is carbamazepine.
77. A formulation as claimed in claim 74 or 75 wherein the further active entity is valproic acid.
78. A formulation as claimed in claim 74 or 75 wherein the further active entity is cimetidine.
79. A formulation as claimed in claim 74 wherein the further active entity is a tryptan.
80. A formulation as claimed in claim 74 or 19 wherein the further active entity is sumatriptan.
81. A formulation as claimed in claim 74 for the treatment of Alzheimers disease wherein the further active entity comprises a cholinesterase inhibitor (such as donepezil, rivastigmine, galantamine) and one or more from the following classes: vitamins, statins, estrogen, nootrophic agents, ginkgo biloba, anti-inflammatory agents, anti-depressants, anti-psychotics, and mood stabilizers.
82. A formulation as claimed in claim 74 wherein the further active entity is selected from one or more of a statin, a thiazidediuretic, a beta blocker, an ACE inhibitor, folic acid, co-enzyme QlO, and an anticoagulant.
83. A formulation as claimed in any of claims 74 to 82 wherein the further active entity is present in a seamless minicapsule.
84. A formulation as claimed in claim 74 to 83 wherein the further active entity is present in at least some of the seamless minicapsules.
85. A formulation as claimed in any of claims 1 to 84 comprising a capsule containing a plurality of minicapsules.
86. A formulation as claimed in claim 85 wherein the capsule contains another entity.
87. A formulation as claimed in claim 86 wherein the other entity is in a liquid, powder, semi-solid, solid or gaseous form.
88. A formulation as claimed in claim 80 or 87 wherein the other entity comprises an active entity.
89. A formulation as claimed in any of claims 1 to 81 comprises a tablet or pellet containing a plurality of minicapsules.
90. A formulation as claimed in claim 89 wherein the tablet or pellet contains another entity.
91. A formulation as claimed in claim 90 wherein the other entity is an active entity.
92. A formulation of a dihydropyrimidine substantially as hereinbefore described.
PCT/IE2005/000105 2004-09-27 2005-09-27 Dihydropyrimidine microcapsule - formulations Ceased WO2006035417A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05786872A EP1814530A2 (en) 2004-09-27 2005-09-27 Dihydropyrimidine microcapsule-formulations
US11/663,836 US20070292523A1 (en) 2004-09-27 2005-09-27 Dihydropyrimidine Formulations
CA002581775A CA2581775A1 (en) 2004-09-27 2005-09-27 Dihydropyrimidine microcapsule - formulations

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US61278504P 2004-09-27 2004-09-27
US61278404P 2004-09-27 2004-09-27
US61278604P 2004-09-27 2004-09-27
US60/612,786 2004-09-27
US60/612,785 2004-09-27
US60/612,784 2004-09-27

Publications (2)

Publication Number Publication Date
WO2006035417A2 true WO2006035417A2 (en) 2006-04-06
WO2006035417A3 WO2006035417A3 (en) 2006-08-31

Family

ID=35636768

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/IE2005/000106 Ceased WO2006035418A2 (en) 2004-09-27 2005-09-27 Microcapsules comprising a methylxanthine and a corticosteroid
PCT/IE2005/000105 Ceased WO2006035417A2 (en) 2004-09-27 2005-09-27 Dihydropyrimidine microcapsule - formulations
PCT/IE2005/000104 Ceased WO2006035416A2 (en) 2004-09-27 2005-09-27 Minicapsule formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IE2005/000106 Ceased WO2006035418A2 (en) 2004-09-27 2005-09-27 Microcapsules comprising a methylxanthine and a corticosteroid

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IE2005/000104 Ceased WO2006035416A2 (en) 2004-09-27 2005-09-27 Minicapsule formulations

Country Status (8)

Country Link
US (4) US20070292523A1 (en)
EP (7) EP2444071A1 (en)
AT (1) ATE413165T1 (en)
CA (3) CA2581775A1 (en)
DE (1) DE602005010899D1 (en)
ES (1) ES2401185T3 (en)
PL (1) PL1811979T3 (en)
WO (3) WO2006035418A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
EP2586428A1 (en) 2007-04-26 2013-05-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
CN103211788A (en) * 2012-01-18 2013-07-24 北京天衡药物研究院 Nifedipine film-controlled slow-release pellet capsule
US9101544B2 (en) 2006-08-30 2015-08-11 Jagotec Ag Controlled release nisoldipine compositions

Families Citing this family (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20030060494A1 (en) * 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
FR2830447B1 (en) * 2001-10-09 2004-04-16 Flamel Tech Sa MICROPARTICULAR ORAL GALENIC FORM FOR DELAYED AND CONTROLLED RELEASE OF PHARMACEUTICAL ACTIVE INGREDIENTS
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
EA200401111A1 (en) * 2002-02-25 2005-02-24 Диффьюжн Фармасьютикалз Ллс TRANS-CAROTINOID BIPOLAR SALTS AND THEIR APPLICATION
CA2480826C (en) 2002-04-09 2012-02-07 Flamel Technologies Oral pharmaceutical formulation in the form of microcapsule aqueous suspension allowing modified release of active ingredient(s)
KR20050005437A (en) * 2002-04-09 2005-01-13 플라멜 테크놀로지스 Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
ES2809302T3 (en) 2004-01-22 2021-03-03 Univ Miami Coenzyme Q10 formulations to treat solid tumors by intravenous administration
EP2444071A1 (en) * 2004-09-27 2012-04-25 Sigmoid Pharma Limited Minicapsule formulations
EP1836665B1 (en) 2004-11-19 2013-01-16 GlaxoSmithKline LLC Method for customized dispensing of variable dose drug combination products for individualizing of therapies
FR2889810A1 (en) * 2005-05-24 2007-02-23 Flamel Technologies Sa ORAL MEDICINAL FORM, MICROPARTICULAR, ANTI-MEASUREMENT
UA95903C2 (en) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Trans carotenoids, their synthesis, formulation and uses
JP2008538354A (en) * 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド Compounds, compositions and methods for treating viral infections and other medical diseases
JP2008535862A (en) * 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド Compounds, compositions and methods for the treatment of poxvirus infections
BRPI0617343A2 (en) * 2005-10-14 2011-07-26 Givaudan Sa fungicidal composition
WO2007047539A2 (en) * 2005-10-14 2007-04-26 Medtronic, Inc. Localized delivery to the lymphatic system
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8685478B2 (en) 2005-11-21 2014-04-01 Philip Morris Usa Inc. Flavor pouch
US9023400B2 (en) * 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
WO2007148340A2 (en) * 2006-06-22 2007-12-27 Mirik Medical Ltd. Adverse drug reaction reduction
WO2008068778A2 (en) * 2006-12-05 2008-06-12 Alembic Limited Extended release pharmaceutical composition of pramipexole
TR201910825T4 (en) * 2006-12-22 2019-08-21 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS TO TREAT MEAL PIPE DISEASES
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2079456B1 (en) 2007-04-04 2012-12-05 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
CN101687757A (en) 2007-04-13 2010-03-31 扩散药品有限公司 Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
CA2685591A1 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8436051B2 (en) * 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
WO2009008006A2 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
KR100869444B1 (en) * 2007-07-11 2008-11-18 주식회사 중외제약 Multi-layered vitamin complex tablet containing ubidecarenone
US8124147B2 (en) * 2007-07-16 2012-02-28 Philip Morris Usa Inc. Oral pouch products with immobilized flavorant particles
US8424541B2 (en) 2007-07-16 2013-04-23 Philip Morris Usa Inc. Tobacco-free oral flavor delivery pouch product
JP2011502125A (en) * 2007-10-31 2011-01-20 ディフュージョン・ファーマシューティカルズ・エルエルシー A new class of treatments that promote small molecule diffusion
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
EP2214679B1 (en) 2007-11-13 2019-03-27 Meritage Pharma, Inc. Corticosteroid compositions
EP2254582B1 (en) * 2008-01-25 2016-01-20 Chimerix, Inc. Methods of treating viral infections
US8729070B2 (en) * 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
WO2009104080A2 (en) * 2008-02-20 2009-08-27 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
KR20100121527A (en) 2008-02-29 2010-11-17 콘서트 파마슈티컬즈, 인크. Substituted xanthine derivatives
KR20100126465A (en) * 2008-03-05 2010-12-01 파나세아 바이오테크 리미티드 Modified Release Pharmaceutical Compositions Comprising Mycophenolate and Methods Thereof
CN102037008B (en) 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 Protease-stabilized, acylated insulin analogs
AU2009233785B2 (en) 2008-04-11 2015-08-20 Berg Llc Methods and use of inducing apoptosis in cancer cells
WO2009134962A2 (en) * 2008-04-30 2009-11-05 The Regents Of The University Of California Claudin-4 binding peptides, compositions and methods of use
WO2009158625A2 (en) * 2008-06-26 2009-12-30 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
IT1393244B1 (en) * 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano SYSTEM FOR THE RELEASE TO COLON OF SUSCEPTIBLE DRUGS OF ENZYMATIC DEGRADATION AND / OR SHORTLY ABSORBED IN THE GASTROINTESTINAL TRACT
US20100056475A1 (en) * 2008-08-06 2010-03-04 Alexander Chucholowski Cyclodextrin conjugates
EP2334295B1 (en) 2008-09-02 2017-06-28 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
WO2010043630A2 (en) * 2008-10-13 2010-04-22 Sigmoid Pharma Limited A delivery system for rna
US20100124560A1 (en) * 2008-11-14 2010-05-20 Mcneil Ab Multi portion intra-oral dosage form and use thereof
WO2010060667A1 (en) * 2008-11-28 2010-06-03 Novo Nordisk A/S Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides
WO2010065489A1 (en) * 2008-12-02 2010-06-10 Sciele Pharma, Inc. Alpha2-adrenergic agonist and angiotensin ii receptor antagonist composition
SI2395991T1 (en) 2009-02-10 2013-12-31 Amarin Pharmaceuticals Ireland Limited Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
WO2010098906A1 (en) * 2009-02-24 2010-09-02 Madeira Therapeutics Liquid statin formulations
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA3186189A1 (en) 2009-05-18 2010-11-25 Dose Medical Corporation Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
ES2649112T3 (en) 2009-05-18 2018-01-10 Sigmoid Pharma Limited Composition comprising drops of oil
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
SG176571A1 (en) * 2009-05-19 2012-01-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
KR101875843B1 (en) * 2009-06-22 2018-07-06 디퓨젼 파마슈티컬즈 엘엘씨 Diffusion enhancing compounds and their use alone or with thrombolytics
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
US8470304B2 (en) 2009-08-04 2013-06-25 Avidas Pharmaceuticals Llc Therapeutic vitamin D sun-protecting formulations and methods for their use
CN107582526A (en) * 2009-08-12 2018-01-16 希格默伊德药业有限公司 Immune regulation composite comprising polymer substrate and oil phase
BR112012006067B1 (en) * 2009-09-17 2019-10-01 Basf Se PREPARATIONS OF WEAKLY SOLUBLE-ACTIVE INGREDIENTS, PROCESS FOR PRODUCTION OF PREPARATIONS, AND DOSAGE FORMS
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US8747562B2 (en) 2009-10-09 2014-06-10 Philip Morris Usa Inc. Tobacco-free pouched product containing flavor beads providing immediate and long lasting flavor release
WO2011048613A2 (en) * 2009-10-12 2011-04-28 Lyka Labs Limited Emergency contraceptive
WO2011053812A1 (en) * 2009-10-30 2011-05-05 Chimerix, Inc. Methods of treating viral associated diseases
AU2010321533A1 (en) * 2009-11-23 2012-05-31 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
KR101891357B1 (en) 2010-06-02 2018-08-24 디퓨젼 파마슈티컬즈 엘엘씨 Oral formulations of bipolar trans carotenoids
CA2706272C (en) * 2010-06-03 2020-05-05 Accucaps Industries Limited Multi phase soft gel capsules, apparatus and method thereof
US20120003312A1 (en) * 2010-06-30 2012-01-05 Aptapharma, Inc. Multilayer Minitablets with Different Release Rates
WO2012025921A1 (en) * 2010-08-23 2012-03-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions for gastric delivery of active agents
GB201015079D0 (en) * 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
ES2386177B1 (en) * 2010-09-21 2013-09-23 Lipotec, S.A. NANOCAPSULES CONTAINING MICROEMULSIONS
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
IT1405998B1 (en) * 2010-12-09 2014-02-06 Bionest Ltd MULTIPURPOSE GEL AGAINST THE VAGINAL DRYNESS WITH A DIRECT AND DELAYED EFFECT
EP2665473A4 (en) * 2011-01-18 2014-08-20 Equine Nutriceuticals Llc Equine nutritional supplement
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
US9433583B2 (en) 2011-04-22 2016-09-06 Frank J. Farrell Colon vitamin
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
CA2877102C (en) * 2011-06-29 2020-06-30 Avidas Pharmaceuticals Llc Topical formulations including lipid microcapsule delivery vehicles and their uses
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US9101547B2 (en) * 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
GB201118182D0 (en) * 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
CN102423483A (en) * 2011-11-24 2012-04-25 西北农林科技大学 A kind of compound ramipril nanoemulsion antihypertensive drug
ITUD20110196A1 (en) * 2011-12-02 2013-06-03 Asoltech S R L COMPOSITION BASED ON UBIDECARENONE
ES2891473T3 (en) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Compositions and methods for reducing high sensitivity levels (hs-CRP) in a subject
JP6203816B2 (en) * 2012-03-29 2017-09-27 セラバイオーム，エルエルシー Gastrointestinal site-specific oral vaccination formulation active against ileum and appendix
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
IN2014DN08443A (en) 2012-04-13 2015-05-08 Concert Pharmaceuticals Inc
JP6855165B2 (en) * 2012-06-15 2021-04-07 コナリス リサーチ インスティチュート アーゲー A pharmaceutical composition containing nicotinic acid and / or nicotinamide and / or tryptophan to have a positive effect on the intestinal microflora.
NZ727849A (en) 2012-06-29 2018-06-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
GB201304662D0 (en) * 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
US20160015647A1 (en) * 2013-03-07 2016-01-21 Capsugel Belgium Nv Bismuth liquid filled hard capsules
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US8652516B1 (en) * 2013-03-15 2014-02-18 Cerovene, Inc. Doxycycline formulations, and methods of treating rosacea
US20140294795A1 (en) * 2013-03-28 2014-10-02 Houn Simon Hsia Nutritional Composition
US9592264B2 (en) * 2013-04-05 2017-03-14 U.S. Nutraceuticals, LLC Delivery system for saw palmetto extract and carotenoid
SG10201903112WA (en) 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
KR102370843B1 (en) 2013-09-04 2022-03-04 버그 엘엘씨 Methods of treatment of cancer by continuous infusion of coenzyme q10
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CA3002989C (en) 2013-10-14 2021-03-16 Nanosphere Health Sciences, Llc Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
CN103565751A (en) * 2013-10-17 2014-02-12 广州帝奇医药技术有限公司 Long-acting sustained-release pellet and preparation method thereof
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CN113750075A (en) 2013-12-06 2021-12-07 英特维特国际股份有限公司 Compositions for oral delivery of bioactive agents
WO2015086838A2 (en) 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
EP3079675B1 (en) 2013-12-13 2020-02-12 CONARIS research institute AG A pharmaceutical composition containing nicotinic acid and/or nicotinamide for use in beneficially influencing blood lipid levels by modifying the intestinal microbiota
US9095607B2 (en) * 2013-12-31 2015-08-04 Antonino Cavallaro Gel for topical application of clove essential oil with broad spectrum anti-inflammatory action and method of preparing same
CN103767070B (en) * 2014-01-15 2015-08-05 中国烟草总公司广东省公司 The preparation method of squalene and astaxanthin composition liquid precursor liposome and fall base harm reduction and apply
CA2938699A1 (en) * 2014-02-05 2015-08-13 Kashiv Pharma Llc Abuse-resistant drug formulations with built-in overdose protection
WO2015130760A1 (en) 2014-02-25 2015-09-03 Orbis Biosciences, Inc. Taste masking drug formulations
CN103859588B (en) * 2014-03-20 2016-04-13 广西中烟工业有限责任公司 The preparation of squalene and astaxanthin composition multivesicular liposome and fall base harm reduction
EP3122348B1 (en) 2014-03-27 2020-05-27 Winterfield, Roland, W. Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
US20170216296A1 (en) 2014-04-18 2017-08-03 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
EP3677229A1 (en) 2014-05-29 2020-07-08 Glaukos Corporation Implants with controlled drug delivery features
CN105294791A (en) * 2014-06-10 2016-02-03 无锡康福特药物科技有限公司 Ultrafine powder of macrolide drug and preparation method for ultrafine powder
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
SG11201609352TA (en) * 2014-06-19 2017-01-27 Solural Pharma ApS Solid oral dosage form of lipophilic compounds
MX2017000384A (en) * 2014-07-09 2017-04-27 Sun Pharmaceutical Ind Ltd Capsule dosage form of metoprolol succinate.
US9700530B2 (en) * 2014-07-09 2017-07-11 Sun Pharmaceutical Industries Limited Capsule dosage form of metoprolol succinate
US11229600B2 (en) * 2014-09-24 2022-01-25 Vital Beverages Global Inc. Compositions and methods for selective GI tract delivery
JP2017530195A (en) * 2014-10-03 2017-10-12 ラケシス・バイオサイエンシーズ・リミテッド Nasal administration compositions for treating neurological and neurodegenerative diseases and disorders
US9980993B2 (en) 2014-11-06 2018-05-29 NWO Stem Cure, LLC Nutraceutical supplement with Lactobacillus rhamnosus
US9468659B2 (en) 2014-11-06 2016-10-18 NWO Stem Cure, LLC Nutraceutical supplement with Lactobacillus rhamnosus
EP3881829A1 (en) 2014-11-07 2021-09-22 Sublimity Therapeutics Limited Compositions comprising cyclosporin
CA3050535C (en) 2014-12-15 2021-11-09 Richard Clark Kaufman Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of anti-inflammatory nutraceuticals
EP3236993B1 (en) 2014-12-23 2023-09-13 Theriva Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
EP3268043A4 (en) * 2015-03-10 2018-12-19 Nanosphere Health Sciences, LLC Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
EP3277419A4 (en) * 2015-04-02 2018-10-31 Nanyang Technological University Tubular and vesicular architectures formed from polymer-lipid blends and method for forming the same
GB201509606D0 (en) * 2015-06-03 2015-07-15 Anabio Technologies Ltd Microencapsulates containing stabilised marine-derived oil, and methods for production thereof
JPWO2017022248A1 (en) * 2015-08-04 2018-05-24 富士カプセル株式会社 Enteric capsule
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US20170119680A1 (en) * 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20170216217A1 (en) * 2016-02-01 2017-08-03 I2O Pharma Ltd. Spherical microcapsules with enhanced oral bioavailability
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US11185523B2 (en) 2016-03-24 2021-11-30 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
EP3442479B1 (en) 2016-04-20 2026-03-04 Glaukos Corporation Bioresorbable ocular drug delivery device
US10092615B2 (en) * 2016-04-30 2018-10-09 Fairhaven Health, Llc Nutritional supplements for improving male fertility
CA3033065A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
TWI700091B (en) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 Insulin containing pharmaceutical compositions
CN110475547A (en) * 2017-03-17 2019-11-19 维塔利斯公司 The composition and method for treating multiple sclerosis
US10214704B2 (en) 2017-04-06 2019-02-26 Baker Hughes, A Ge Company, Llc Anti-degradation and self-healing lubricating oil
TW201900160A (en) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 Compositions and Methods for Lowering Triglycerides in a Subject Having Reduced Kidney Function
WO2019032573A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
FI3668927T3 (en) * 2017-09-12 2024-04-05 Eth Zuerich Transmembrane ph-gradient polymersomes for the quantification of ammonia in body fluids
CN111655770A (en) * 2017-12-01 2020-09-11 电缆元件集团有限责任公司 Foamable compositions and methods for making foam articles
US11564910B2 (en) 2017-12-08 2023-01-31 Adamis Pharmaceuticals Corporation Drug compositions
AU2018390826B2 (en) 2017-12-20 2024-09-12 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
CA3087569A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
BR112020017090A8 (en) 2018-02-23 2022-07-05 Crestovo Holdings Llc MICROBIOME-RELATED IMMUNOTHERAPIES
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2019178542A1 (en) * 2018-03-16 2019-09-19 Persephone Biome, Inc. Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
TWI657825B (en) * 2018-04-04 2019-05-01 美進醫藥公司 Pharmaceutical compositions and methods of treating cardiovascular disease
EP3781151A1 (en) * 2018-04-17 2021-02-24 Université de Caen Normandie Bambuterol for the treatment of alzheimer's disease
CA3102643A1 (en) * 2018-06-08 2019-12-12 Harrow Ip, Llc Pyrimethamine-based pharmaceutical compositions and methods for fabricating thereof
US11266615B2 (en) 2018-06-08 2022-03-08 Harrow Ip, Llc Pyrimethamine-based pharmaceutical compositions and methods for fabricating thereof
LT3750536T (en) 2018-09-24 2026-03-25 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
CA3119037A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN110025611A (en) * 2019-03-14 2019-07-19 吉林大学 A kind of Quercetin to tyrosine phosphatase 1B inhibit in application
EP3979985A4 (en) * 2019-06-07 2023-05-03 Paxmedica, Inc. Compositions and methods for treating central nervous system disorders
CA3146738A1 (en) 2019-07-18 2021-01-21 Synthetic Biologics, Inc. Intestinal alkaline phosphatase-based treatments of metabolic disorders
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
US20210023023A1 (en) * 2019-07-25 2021-01-28 Vasayo, Llc Liposomal nutraceutical compositions and methods of making the same
CN114650833A (en) 2019-09-13 2022-06-21 芬奇治疗控股有限责任公司 Compositions and methods for treating autism spectrum group disorders
AU2020366529A1 (en) 2019-10-18 2022-05-19 Finch Therapeutics Holdings Llc Compositions and methods for delivering a bacterial metabolite to a subject
BR112022009189A2 (en) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd METHODS TO REDUCE THE RISK OF CARDIOVASCULAR EVENT IN A SUBJECT WITH ATRIAL FIBRILLATION AND/OR ATRIAL PALPITATION
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
CN110951801B (en) * 2019-11-25 2021-04-13 北京工商大学 Application of polyoxyethylene lauryl ether in production of monacolin K
TW202140049A (en) 2020-01-10 2021-11-01 美商芬奇治療控股有限責任公司 Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv)
WO2021142358A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatic encephalopathy (he)
WO2021142347A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
WO2021144625A1 (en) * 2020-01-18 2021-07-22 Maneesh Pharmaceuticals Ltd The oral synergistic composition and its process for the preparation
US20210275531A1 (en) * 2020-03-04 2021-09-09 VK Research Associates Inc Phosphodiesterase-5 inhibitor combinations, methods of making, and methods of use thereof
JP7785682B2 (en) * 2020-03-18 2025-12-15 アール．ピー．シェーラー テクノロジーズ，エルエルシー Softgel capsules
WO2021202806A1 (en) 2020-03-31 2021-10-07 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
US12360428B2 (en) 2020-04-13 2025-07-15 Massachusetts Institute Of Technology Melanin-peptide-based photonic materials
EP4135740A4 (en) * 2020-04-16 2024-05-22 The Medical College of Wisconsin, Inc. AEROSOLATED FORMULATIONS OF HIV PROTEASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY TRACT REFLUX
US20240261360A1 (en) * 2020-05-25 2024-08-08 Metaceutic Aps Nutraceutical composition
WO2021247601A1 (en) * 2020-06-02 2021-12-09 Model Medicines, Inc. Methods and compositions for treating rna viral infections
US20220054402A1 (en) * 2020-11-05 2022-02-24 Richard C Kaufman Compositions and methods for extracting, stabilizing, and manufacturing stable dosage forms of psilocin, psychedelic drugs, entheogens, and medicinal mushrooms as nano-dimensional drug delivery structures
US20240263251A1 (en) 2021-02-19 2024-08-08 Finch Therapeutics Holdings Llc Compositions and methods for providing secondary bile acids to a subject
WO2022204757A1 (en) * 2021-03-30 2022-10-06 Noxopharm Limited Improved isoflavone formulation
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CN113244197B (en) * 2021-05-24 2023-02-28 天方药业有限公司 Carbamazepine sustained-release capsule and preparation method thereof
US12005185B2 (en) * 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods
US20230233467A1 (en) * 2022-01-24 2023-07-27 Nutraceutical Corporation Multiple nutrient liposomal supplement and methods of manufacturing the same
US20250213497A1 (en) * 2022-03-30 2025-07-03 Amrita Vishwa Vidyapeetham A nano in micro formulation and process thereof
CA3250702A1 (en) * 2022-05-03 2023-11-09 Nocion Therapeutics, Inc. Compositions and methods for treatment of inflammatory bowel disease
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI65914C (en) * 1978-03-07 1984-08-10 Sandoz Ag FRAMEWORK FOR PHARMACEUTICAL COMPOSITION OF CYCLOSPORINE A
US4279632A (en) * 1979-05-08 1981-07-21 Nasa Method and apparatus for producing concentric hollow spheres
IT1148784B (en) * 1980-04-09 1986-12-03 Eurand Spa PROCEDURE FOR THE PREPARATION OF MICRO CAPSULES IN A LIQUID VEHICLE
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
DE3224619A1 (en) * 1981-07-14 1983-05-19 Freund Industrial Co., Ltd., Tokyo Oral pharmaceutical composition
US4481157A (en) * 1982-04-27 1984-11-06 Morishita Jintan Co., Ltd. Method and apparatus for production of microcapsules
US4597959A (en) * 1982-04-30 1986-07-01 Arthur Barr Sustained release breath freshener, mouth and palate coolant wafer composition and method of use
JPS5953410A (en) * 1982-09-20 1984-03-28 Fujisawa Pharmaceut Co Ltd Novel soft capsule agent
US4422985A (en) * 1982-09-24 1983-12-27 Morishita Jintan Co., Ltd. Method and apparatus for encapsulation of a liquid or meltable solid material
JPS59131355A (en) * 1983-01-17 1984-07-28 森下仁丹株式会社 Multiple soft capsule
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
DE3331009A1 (en) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen METHOD FOR INCREASING THE ENTERAL RESORBABILITY OF HEPARIN OR. HEPARINOIDS AND THE SO AVAILABLE HEPARIN OR HEPARINOID PREPARATION
JPS60100516A (en) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4565161A (en) * 1985-04-08 1986-01-21 Uraken Canada Limited Steam generation
US4749574A (en) * 1986-04-14 1988-06-07 Fujisawa Pharmaceutical Co., Ltd. Sustained-release transdermal delivery preparations
US4749454A (en) * 1986-11-17 1988-06-07 Solarex Corporation Method of removing electrical shorts and shunts from a thin-film semiconductor device
US4857335A (en) * 1987-03-27 1989-08-15 Lim Technology Laboratories, Inc. Liquid controlled release formulations and method of producing same via multiple emulsion process
KR920003601B1 (en) * 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 Composition of Eye Drop Cyclosporin
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
JP2806564B2 (en) * 1989-07-20 1998-09-30 森下仁丹株式会社 SEAMLESS CAPSULES CONTAINING A HYDROPHILIC SUBSTANCE AND METHOD OF PRODUCING THE SAME
US5260071A (en) * 1989-12-18 1993-11-09 Lemelson Jerome H Drug units and methods for using same
ATE103806T1 (en) * 1990-07-04 1994-04-15 Shionogi & Co PROCESS FOR MAKING A NON-COHAESIVE COATING.
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5418010A (en) * 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP3313124B2 (en) * 1991-07-31 2002-08-12 森下仁丹株式会社 SEAMLESS CAPSULES CONTAINING A HYDROPHILIC SUBSTANCE AND PROCESS FOR PRODUCING THE SAME
DE4201179A1 (en) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Granulates or pellets comprising dispersion of active agent in hydrophilic macromolecules - are e.g. for treatment of depression, hypertension, rheumatism, etc.
US5571533A (en) * 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
AU3941493A (en) * 1992-03-30 1993-11-08 Alza Corporation Viscous suspensions of controlled-release drug particles
DE69324523T2 (en) * 1992-06-12 1999-09-09 Kao Corp. Seamless capsule containing bath additive composition containing surfactants and method of making the capsule
JP3405746B2 (en) * 1992-10-28 2003-05-12 フロイント産業株式会社 Manufacturing method of seamless capsule
GB9300875D0 (en) * 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
US5843347A (en) * 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2707184B1 (en) * 1993-07-08 1995-08-11 Rhone Poulenc Nutrition Animal Process for the preparation of spherules containing an active food or pharmaceutical ingredient.
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
DE4332041C2 (en) * 1993-09-21 1997-12-11 Rentschler Arzneimittel Use of pentoxifylline in certain lung diseases
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2721510B1 (en) * 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticles filterable under sterile conditions.
US5650232A (en) * 1994-10-07 1997-07-22 Warner-Lambert Company Method for making seamless capsules
FR2725623A1 (en) * 1994-10-18 1996-04-19 Flamel Tech Sa MEDICINAL AND / OR NUTRITION MICROCAPSULES FOR PER OS ADMINISTRATION
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
US5529783A (en) * 1994-12-19 1996-06-25 Mcneil-Ppc, Inc. Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
KR0167613B1 (en) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 Cyclosporine-containing soft capsule composition
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5674495A (en) * 1995-02-27 1997-10-07 Purdue Research Foundation Alginate-based vaccine compositions
US5595757A (en) * 1995-03-29 1997-01-21 Warner-Lambert Company Seamless capsules
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
DE19544507B4 (en) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin containing preparations
JP3759986B2 (en) * 1995-12-07 2006-03-29 フロイント産業株式会社 Seamless capsule and manufacturing method thereof
US5686133A (en) * 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
CA2288876A1 (en) * 1997-05-06 1998-11-12 Xiao Yu Wu Drug delivery system
JP4102459B2 (en) * 1997-05-14 2008-06-18 森下仁丹株式会社 Seamless capsule for synthesizing biopolymer and method for producing the same
SE9702533D0 (en) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
ES2137862B1 (en) * 1997-07-31 2000-09-16 Intexim S A ORAL PHARMACEUTICAL PREPARATION INCLUDING A COMPOUND OF ANTI-ULCER ACTIVITY AND PROCEDURE FOR ITS OBTAINING.
JP3090198B2 (en) * 1997-08-21 2000-09-18 日本電気株式会社 Structure of semiconductor device and method of manufacturing the same
KR100569319B1 (en) * 1997-10-30 2006-04-07 모리시타 진탄 가부시키가이샤 Capsule preparation containing unsaturated fatty acid or derivatives thereof and method for producing same
IT1296585B1 (en) * 1997-11-28 1999-07-14 Uni Di Pavia MICROCAPS CONTAINING SEMINAL MATERIAL FOR INSTRUMENTAL INSEMINATION IN THE SWINE SPECIES
US6509346B2 (en) * 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US20040062802A1 (en) * 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
US6174466B1 (en) * 1998-05-08 2001-01-16 Warner-Lambert Company Methods for making seamless capsules
JPH11322587A (en) * 1998-05-18 1999-11-24 Sumitomo Chem Co Ltd Method for microencapsulating a physiologically active substance solid at room temperature and microcapsule composition obtained by this method
KR100336090B1 (en) * 1998-06-27 2002-05-27 윤승원 Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof
JP3039863B1 (en) * 1998-12-25 2000-05-08 不二精工株式会社 Locking press device
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
AU4428000A (en) * 1999-05-14 2000-12-05 Coraltis Ltd. Pulse-delivery oral compositions
CA2376261A1 (en) * 1999-06-09 2000-12-14 Mochida Pharmaceutical Co., Ltd. System for release in lower gastrointestinal tract
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PT1280521E (en) * 2000-05-12 2005-10-31 Pharmacia & Upjohn Co Llc VACCINE COMPOSITION, METHOD FOR PREPARATION, AND METHOD OF VACCINATION OF VERTEBRATES
US20040258702A1 (en) * 2000-06-22 2004-12-23 Blonder Joan P. Vaccine delivery
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
US6565888B1 (en) * 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
FI20002215A0 (en) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination Particles
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
FR2830447B1 (en) * 2001-10-09 2004-04-16 Flamel Tech Sa MICROPARTICULAR ORAL GALENIC FORM FOR DELAYED AND CONTROLLED RELEASE OF PHARMACEUTICAL ACTIVE INGREDIENTS
US6951655B2 (en) * 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
JP4226846B2 (en) * 2002-06-07 2009-02-18 キャタレント・ジャパン株式会社 Soft capsule that can disintegrate in the oral cavity
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
CA2520660C (en) * 2003-03-28 2013-08-20 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
KR100720213B1 (en) * 2003-04-04 2007-05-21 화이자 프로덕츠 인코포레이티드 Microfluidized oil-in-water emulsions and vaccine compositions
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
PE20060003A1 (en) * 2004-03-12 2006-03-01 Smithkline Beecham Plc POLYMERIC PHARMACEUTICAL FORMULATION FOR INJECTION MOLDING
GB0417481D0 (en) * 2004-08-05 2004-09-08 Etiologics Ltd Combination therapy
EP2444071A1 (en) * 2004-09-27 2012-04-25 Sigmoid Pharma Limited Minicapsule formulations
JP2008534591A (en) * 2005-03-29 2008-08-28 マクニール−ピーピーシー・インコーポレーテツド Composition having a hydrophilic drug in a hydrophobic solvent
US7842312B2 (en) * 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20080124279A1 (en) * 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
KR100895200B1 (en) 2006-08-24 2009-04-24 한올제약주식회사 Controlled release complex formulation comprising dihydropyridine calcium channel blockers and HMG-CoA reductase inhibitors
US9101544B2 (en) 2006-08-30 2015-08-11 Jagotec Ag Controlled release nisoldipine compositions
US9622980B2 (en) 2006-08-30 2017-04-18 Jagotec Ag Controlled release compositions
EP2586428A1 (en) 2007-04-26 2013-05-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
CN103211788A (en) * 2012-01-18 2013-07-24 北京天衡药物研究院 Nifedipine film-controlled slow-release pellet capsule

Also Published As

Publication number Publication date
WO2006035418A3 (en) 2006-08-31
EP2322146A3 (en) 2011-06-15
EP2444071A1 (en) 2012-04-25
US20140234410A1 (en) 2014-08-21
US20080113031A1 (en) 2008-05-15
EP2153824A1 (en) 2010-02-17
CA2581764A1 (en) 2006-04-06
EP1811979B1 (en) 2008-11-05
ATE413165T1 (en) 2008-11-15
WO2006035417A3 (en) 2006-08-31
CA2581775A1 (en) 2006-04-06
EP2322146B1 (en) 2012-12-12
WO2006035418A2 (en) 2006-04-06
EP2156826A1 (en) 2010-02-24
WO2006035416A3 (en) 2007-03-15
EP1811979A2 (en) 2007-08-01
ES2401185T3 (en) 2013-04-17
CA2581816A1 (en) 2006-04-06
US20080020018A1 (en) 2008-01-24
PL1811979T3 (en) 2009-04-30
WO2006035416A2 (en) 2006-04-06
DE602005010899D1 (en) 2008-12-18
EP1814530A2 (en) 2007-08-08
US20070292523A1 (en) 2007-12-20
EP1802287A2 (en) 2007-07-04
EP2322146A2 (en) 2011-05-18

Similar Documents

Publication Publication Date Title
US20070292523A1 (en) Dihydropyrimidine Formulations
EP1094790B9 (en) Sustained release pharmaceutical preparation comprising phenytoin sodium
EP2359817B1 (en) Solid oral dosage form containing seamless microcapsules
EP1248599B1 (en) Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
CN101686948B (en) Cyclosporin pharmaceutical composition
CN101410094B (en) Drug delivery system comprising a weakly basic selective serotonin 5-HT3 blocker and an organic acid
CN1886119B (en) Pantoprazole multiparticulate formulations
EP2872123B1 (en) Enteric coated multiparticulate controlled release peppermint oil composition and related methods
JP2008303223A (en) Oral pulsed dose drug delivery system
KR101380507B1 (en) Solid oral form with dual release profile, containing multiparticulates
US9707260B2 (en) Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US11207276B2 (en) Multiparticulate L-menthol formulations and related methods
JP4660192B2 (en) Spheroid, method for producing the same, and pharmaceutical composition
JPH0451528B2 (en)
WO2004024128A2 (en) Modified release ketoprofen dosage form
CZ118899A3 (en) A sustained release composition, a method of preparing the composition, a method of improving drug release profile, and using the composition
KR20000053326A (en) Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IE20050644A1 (en) Dihydropyrimidine formulations
WO2010036975A2 (en) Dipyridamole and acetylsalicylic acid formulations and process for preparing same
Dulin Oral targeted drug delivery systems: enteric coating
IE902554A1 (en) Aspirin granules with gastroprotectant coating
CN101132782A (en) Oral pharmaceutical dosage forms of losartan
MXPA99002404A (en) Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2. 2]oct-3-yl)acetonitrile monohydrochloride

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2581775

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11663836

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005786872

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005786872

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11663836

Country of ref document: US